Skip to main content
Advanced Science logoLink to Advanced Science
. 2019 Oct 14;6(22):1901724. doi: 10.1002/advs.201901724

Smart H2S‐Triggered/Therapeutic System (SHTS)‐Based Nanomedicine

Weiyu Chen 1, Dalong Ni 1,, Zachary T Rosenkrans 2, Tianye Cao 1, Weibo Cai 1,2,
PMCID: PMC6864508  PMID: 31763153

Abstract

Hydrogen sulfide (H2S) is of vital importance in several biological and physical processes. The significance of H2S‐specific detection and monitoring is emphasized by its elevated levels in various diseases such as cancer. Nanotechnology enhances the performance of chemical sensing nanoprobes due to the enhanced efficiency and sensitivity. Recently, extensive research efforts have been dedicated to developing novel smart H2S‐triggered/therapeutic system (SHTS) nanoplatforms for H2S‐activated sensing, imaging, and therapy. Herein, the latest SHTS‐based nanomaterials are summarized and discussed in detail. In addition, therapeutic strategies mediated by endogenous H2S as a trigger or exogenous H2S delivery are also included. A comprehensive understanding of the current status of SHTS‐based strategies will greatly facilitate innovation in this field. Lastly, the challenges and key issues related to the design and development of SHTS‐based nanomaterials (e.g., morphology, surface modification, therapeutic strategies, appropriate application, and selection of nanomaterials) are outlined.

Keywords: gas delivery, H2S‐specific detection, H2S‐triggered therapy, hydrogen sulfide, novel nanoplatforms


H2S‐specific nanoagents are of vital importance in detecting endogenous and exogenous H2S gas. The recent developments of these smart H2S‐triggered/therapeutic systems (SHTSs) are summarized. Additionally, the challenge faced, and the principals involved, are further discussed for future H2S‐nanoprobe designs.

graphic file with name ADVS-6-1901724-g021.jpg

1. Introduction

Hydrogen sulfide (H2S) is a highly toxic gas known for its causticity, flammability and distinct odor of rotten eggs.1, 2, 3 However, endogenous H2S is the third major gasotransmitter in addition to carbon monoxide (CO) and nitric oxide (NO).4, 5, 6 The misregulation of this signaling molecule is associated with numerous diseases, such as Alzheimer's disease, diabetes, and cancer.7, 8 Since H2S has such a crucial role, an effective H2S detection method would facilitate the understanding of the implicated diseases permit early diagnosis. Currently, the most‐used techniques include high‐pressure liquid/gas chromatography (HPLC/GC) have shown significant sensitivity. However, the high cost and tediously processing time severely restrict their practical application in detecting H2S in biological samples, especially for real‐time measurements. In comparison, novel small molecules ranging from colorimetric and fluorescent probes have demonstrated substantial advantages for dynamic and in situ H2S sensing/imaging via various chemical strategies.9 Several fluorescent probes, such as sulfidefluor‐1/2 (SF‐1/2) and hydrogen sulfide imaging probe‐1 (HSip‐1) present desirable selectivity and can “turn on” an H2S‐activated fluorescent signal for H2S detection (e.g., living cell imaging), with limits of detection (LOD) (all the abbreviations could be found in Table 1 ) reported around 5 × 10−6–10 × 10−6 m.10, 11, 12 While well‐designed small molecule probes have been applied for H2S‐selective detection in live cells and in vivo imaging,13, 14 they still present issues such as the relatively low sensitivity and selectivity, poor water solubility, weak fluorescent intensity,13 and poor circulation (e.g., the accumulation in liver) that must be overcome.14

Table 1.

Full names and the corresponding abbreviations

Full name Abbreviation Full name Abbreviation
3‐mercaptopyruvate sulfotransferase 3‐MST Myocardial infarction MI
Aerosol‐assisted chemical vapor deposition AACVD Metal‐organic frameworks MOF
Alzheimer's Disease AD 11‐mercaptoundecanoic acid MUA
Anethole dithiolethione ADT Mesoporous silica nanoparticles MSNs
Aggregation‐induced emission AEI Near Infrared NIR
Anethole dithiolethione (ADT)‐loaded magnetic nanoliposome AMLs Noble metal clusters NMCs
Amino‐oxyacetic acid AOAA Photoacoustic PA
Adenosine triphosphate ATP Positron emission tomography PET
Carbon nanodots C‐dot Photodynamic therapy PDT
Cystathionine β‐synthase CBS Polymeric nanoparticles PMNs
Carbon nanotubes CNTs Plasmonic nanoparticles PNPs
Cystathionine γ‐lyase CSE Polystyrene sulfonate PSS
Diallyl sulfide DATS Photothermal therapy PTT
Functional graphene sheets FGS Reactive oxygen species ROS
Ischemia/reperfusion I/R S‐adenosyl‐l‐methionine SAM
Inner filter effect IFE Smart H2S‐triggered/therapeutic system SHTS
Intercellular adhesion molecule‐1 ICAM‐1 Tris(2‐chloroisopropyl)phosphate TCPP
Limits of detection LOD 3,3′,5,5′‐tetramethylbenzidine TMB
Liposome nanoparticles LNPs 1‐(10‐mercaptodecyl)‐5‐methylpyrimidine‐2,4‐dione TSH
Luminescence/Förster resonance energy transfer LRET/FRET Triphenyltetrazolium chloride TTC
Longitudinal surface plasmon resonance's LSPR Upconverting nanoparticles UCNPs
Vascular cell adhesion molecule‐1 VCAM‐1 Upconversion luminescence UCL

During the recent two decades, nanomaterials have drawn substantial global attention.15, 16, 17, 18, 19 Due to their desirable physiochemical features (e.g., high biocomparability and stability, large specific surface area, excellent loading efficiency, variable modification, etc.),20, 21, 22 nanomaterials have been widely employed in various biomedical applications in drug delivery, vaccination, imaging, and therapy.23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33 With careful design, nanoplatforms can exceed small molecule probes as ideal sensing agents for rapid, selective, and efficient H2S detection.34, 35, 36, 37 Recently, novel nanoprobes have been developed for H2S sensing, which efficiently detect and image hydrogen sulfide via 1) chemical features of the loaded smart fluorophore (e.g., Aziede reduction, metal precipitation and nucleophilic attack),38, 39, 40 2) change of localized surface plasmon resonance's (LSPR),41, 42, 43 3) variation of absorbance (colorimetric assay),44 4) surface metal precipitation,45, 46, 47 5) change of luminescence/Förster resonance energy transfer (LRET/FRET),48, 49, 50 or 6) electrochemical reaction.51, 52, 53 More importantly, a series of therapeutic strategies (e.g., photothermal therapy and photodynamic therapy, etc.) could be intelligently triggered by the activation of endogenous H2S from the targeting area.54, 55 Additionally, exogenous H2S delivery has been successfully achieved via nanoplatforms, which can induce H2S‐mediated gas therapy (via physical damage) or tissue protection (e.g., the heart I/R injury) within the disease regions.56, 57 These multifunctional nanoplatforms may generate novel treatments available for various H2S‐related diseases.

As such a promising field, smart H2S‐triggered/therapeutic system (SHTS)‐based nanomedicine is expected to significantly accelerate the development of disease diagnosis and therapeutic strategy by enhancing accuracy and efficiency. Given the vital role of hydrogen sulfide in biological processes and advantages of nanotechnology, we provide an overview of recent progress in H2S detection, imaging and related disease therapy via SHTS‐based nanomedicine (Figure 1 ). Within this review, various nanoagents such as noble metal nanomaterials, metal‐organic framework, copper‐based nanomaterials, and carbon nanodot for H2S sensing, different imaging (including fluorescence, localized surface plasmon resonance, upconversion luminescence, near‐infrared, photoacoustic and positron emission tomography imaging) and therapeutic strategies (e.g., the endogenous H2S‐triggered therapy or exogenous H2S delivery) are summarized. As such, we aim to highlight these powerful nanoprobes in this emerging field and offer an overview for the development of next‐generation of SHTS‐based nanomedicine.

Figure 1.

Figure 1

The H2S‐specific detection, imaging, and therapy mediated by the smart H2S‐triggered/therapeutic system (SHTS).

2. Roles of H2S in Biological Systems

Endogenous H2S is mainly produced from cysteine by three enzymes: 3‐mercaptopyruvate sulfotransferase (3‐MST), cystathionine β‐synthase (CBS), and cystathionine γ‐lyase (CSE).58, 59, 60, 61 The H2S generated is a vital gas transmitter that affects various biological and physical functions within the body, ranging from antiinflammation to regulation of neuronal transmission.62, 63, 64, 65 For instance, it has been reported that H2S donors promote the production of ATP and electron transport in mitochondrial.66 Furthermore, H2S is able to protect the cell by attenuating apoptosis.

Thus, it has been widely applied as a novel reagent for preserving organs from ischemia‐reperfusion injury during various surgeries and organ transplantations.67, 68, 69 Also, the increased secretion of endogenously H2S is strongly associated with the progress of tumor.4, 70

Notably, the H2S generating enzymic system including 3‐MST, CBS, and CSE have been widely identified in many cancer types.4, 71 The overexpression of CBS has been particularly reported within various colon and ovarian cancers,72, 73 indicating the significant role of H2S in promoting tumor development. The hydrogen sulfide derived from cancer cells also promotes tumor growth and proliferation by acting as an autocrine and paracrine factor.72 After introducing a CBS inhibitor, the growth of colon cancer could be greatly attenuated by efficiently reducing H2S generation and inhibiting peritumor angiogenesis.61 However, the fast catabolism and regulation of this toxic gas show a great challenge for real‐time detection within the tissues.74 As one of the most dangerous gases, the concentration of H2S within the air needs to be monitored as well. While this toxic gas easily noted because of its rotten‐egg smell, the exposure to H2S can cause a serial of symptoms including lung irritations (≤20 ppm), damage of eye (300–500 ppm), unconsciousness, or even death (≥700 ppm).75 Therefore, successful detection/imaging of hydrogen sulfide would be immensely valuable for disease diagnosis and treatment, as well as risk management.

3. H2S Detection with SHTS‐Based Nanomedicine

To monitor H2S in solutions and air, various nanomaterials have been developed as novel sensors, including noble metal nanoparticles (e.g., Au, Ag, and Au/Ag alloy), metal‐organic frameworks (MOF), copper nanomaterials, carbon nanodots, among others (e.g., ruthenium nanoparticles, etc.). In this section, a series of SHTS‐based nanosensors will be summarized (Table 2 ).

Table 2.

The nanosized materials as SHTS for H2S detection

Material a) Nanoparticle Size [nm] Mechanism Assay Sample Phase LOD Ref.
Au Au NRs ≈60 Aggregation Colorimetry (A730) Solution 24 × 10−6 m 76
AEAuNPs 13.3 ± 1.6 Aggregation Colorimetry (A520/720) Solution 20 × 10−6 m 44
GSH‐AuNP 13 Aggregation Colorimetry (A700/520) Solution 3 × 10−6 m 77
BSA‐AuNCs‐HSIP‐1 ≈1 Aggregation Metal precipitation (I519/I632) Solution 0.73 × 10−6 m 78
TSH‐MUA‐ AuNDs 1.9 ± 0.3 Antiaggregation Fluorescence (Em510) Solution 0.5 × 10−6 m 79
Cu@Au NPs N/A Competitive binding Colorimetry (A650/520) Solution 0.3 × 10−6 m 80
AuS/Au NPs N/A Reduction Colorimetry (A414) Solution 0.28 × 10−6 m 81
FSN‐AuNRs 30.8 ± 2 × 12.5 ± 1 Aggregation Colorimetry (A518/A648) Solution, Serum 0.2 × 10−6 m 82
Au NPs 8.1 ± 1.1 Catalyst Colorimetry (A652) Solution 80 × 10−9 m 83
Au NPs 13 Antiaggregation Colorimetry (A520) Bubble gas 30 × 10−9 m 84
Au@TPt‐NCs 17.1 Catalyst Colorimetry (A650) Solution/Evaporated gas 7.5 × 10−9 m 85
Au/Ag Core–shell Au@Ag NCs ≈1.8 Quench of the fluorescence Fluorescence (Em650) Solution 0.31 × 10−6 m 86
DNA‐Au/Ag NCs 1.6 Quench of the fluorescence Fluorescence (Em440) Solution 0.83 × 10−9 m 87
Ag C314‐Ag NPs 6–14 Reduction Fluorescence (Em493) Solution ≈60 ppb 88
Chit‐AgNPs 9 ± 2.5 LSPR change Colorimetry (A404) Solution 0.35 × 10−6 m 42
PPF cage‐AgNPs 6–8.4 LSPR change Colorimetry (A400) Solution 0.2 × 10−6 m 43
MOF Eu3+/Cu2+@UiO‐66‐(COOH)2 80–100 Metal precipitation Fluorescence (I615/I393) Solution 5.45 × 10−6 m 46
Tb3+@Cu‐MOF N/A Metal precipitation Fluorescence (I544/I390) Solution 1.2 × 10−6 m 89
[[EuCu(pydc)2(ox)0.5(H2O)3·1.5H2O]2n N/A Catalyst Fluorescence (Em615) Solution, Serum 130 × 10−9 m 90
Al‐MIL‐53‐NO2 MMMs 60–80 Reduction Fluorescence (Em466) Solution 92.31 × 10−9 m 39
Zr(TBAPy)5(TCPP) ≈100 Reduction Fluorescence (≈Em440) Solution 1 ppb 91
Cu‐SWCNTs N/A Reduction Electrochemistry Solution 5 ppm 92
Cu p‐CuO/n‐SnO2 NWs 200 (CuO) Breakup of pn junction Electrochemistry Gas 1 ppm 93
Quasi‐2D Cu2O/SnO2 N/A Reduction Electrochemistry Gas 0.5 ppm 94
Cu2O‐WO3 NDs 2–3 (Cu2O) Reduction Electrochemistry Gas 300 ppb 53
PSS‐PAE‐Cu NCs 173 Aggregation Fluorescence (Em665) Solution 650 × 10−9 m 95
Cu2O–FGS 3 (Cu2O) Reduction Electrochemistry Gas 5 ppb 52
Cysteine‐Cu NCs 2.5 Aggregation Fluorescence (Em460) Solution 42 × 10−9 m 96
C‐dot CD‐Hg2+/Ag+ 7.6 Quench of the fluorescence Fluorescence (Em440) Solution 0.32/0.43 × 10−6 m 97
Ag–C‐dot ≈5 Electrochemiluminescence Electrochemistry Solution 0.027 × 10−6 m 51
GBR N/A Catalyst Colorimetry (A652) Solution 25.3 × 10−6 m 98
PPy/WO3 50–70 Reduction Electrochemistry Solution 100 ppb 99
SnO2/rGO ≈4 Chemisorption Electrochemistry Gas 43 ppb 100
Others Cyclen‐FPNs 33–40 Metal precipitation Fluorescence (Em540) Solution 2.1 × 10−6 m 101
Pb2+‐MoS2 nanosheet N/A Quench of the fluorescence Fluorescence (Em406) Solution 0.42 × 10−6 m 102
PbO/SiO2 50–100 Quench of the fluorescence Fluorescence (Em510) Solution 0.138 × 10−6 m 103
Ru NPs 1.7 ± 0.2 Catalyst Colorimetry (A512) Solution 0.6 × 10−9 m 44
a)

LSPR: localized surface plasmon resonance; NCs: nanocluster; NRs: nanorods; NDs: nanodots; NWs: nanowires; NNs: nanoneedles.

3.1. Noble Metal Nanomaterials

Gold and silver are two major noble metals that have been widely used in daily life for centuries. For instance, colloidal gold is a well‐known dye for glass staining that can be traced back to the Roman era. With the excellent stability, catalytic ability, and optical properties, gold, silver, and alloy nanomaterials have been widely developed and applied for biomedical engineering applications.43, 85, 87 The LSPR is a key characteristic of noble metal nanomaterial that is easily influenced by the size, distance, and composition.104 Based on this property, a variety of detection methods have been developed by the formation/dispersion of aggregation or change of the surface, including the specific detection for hydrogen sulfide (Table 2).

With proper surface functionalization using different ligands such as glutathione,77 fluorosurfactants,82 or small molecules (e.g., thiolated azido derivates and active esters),44 gold nanosensors quickly aggregate when they encounter with H2S. This results in a redshift of absorbance wavelengths and LOD ranging from 0.2 × 10−6 to 20 × 10−6 m. In comparison, hydrophobic surface modification (e.g., fluorescent probe, 1‐(10‐mercaptodecyl)‐5‐methylpyrimidine‐2,4‐dione, TSH) force the AuNDs coated with TSH and MUA (11‐mercaptoundecanoic acid) to aggregate. The presence of H2S could disassemble the aggregation surface adsorption of H2S and HS, recovering the quantum yield back to 1.61%.79 Similarly, Zhang et al. developed a simple sensing strategy by using bubbling H2S to stabilize the AuNPs (13 nm), with the existence of NaCl (80 × 10−3 m) and Tween 80 (Figure 2 A).84 This cost‐effective method provides a high sensitivity toward H2S with LOD values reaching around 14 × 10−6 m for the naked eye and 30 × 10−9 m for machine detection, which is more efficient than that afforded by TSH‐MUA‐AuNDs (0.5 × 10−6 m).

Figure 2.

Figure 2

A) The scheme of AuNPs for detecting bubbling H2S with the coordination of NaCl and Tween‐80. Reproduced with permission.86 Copyright 2014, American Chemical Society. B) Schematic demonstration of the Au@TPt‐NCs‐based platform for detecting dissolved hydrogen sulfide via a colorimetric strategy. C) The deactivated assays of Au@TPt‐NCs (Au core @ ultrathin platinum shell nanoclusters) via H2S (the testing groups included: a) Au@TPt‐NCs; b) H2O2 + TMB (3,3′,5,5′‐tetramethylbenzidine); c) 0.1 × 10−6 m H2S; d) Au@TPt‐NCs + H2O2 + TMB; e) Au@TPt‐NCs + 0.1 × 10−6 m H2S; f) Au@TPt‐NCs + 0.1 × 10−6 m H2S + H2O2 + TMB; g) Au@TPt‐NCs + 0.5 × 10−6 m H2S + H2O2 + TMB); h) Au@TPt‐NCs + 1 × 10−6 m H2S + H2O2 + TMB); D) the detection of H2S at various concentrations (a) 0 × 10−6 m; b) 0.1 × 10−6 m; c) 0.2 × 10−6 m; d) 0.5 × 10−6 m) via the catalysis of Au@TPt‐NCs platform (n = 3). Reproduced with permission.87 Copyright 2015, American Chemical Society. E,F) Schematic illustration of DNA‐Au/Ag NCs Probe's synthesis and detection of H2S; H2S‐induced fluorescent quenching of DNA‐Au/Ag NCs in the presence of S2− ions over G) 0 × 10−6 –0.01 × 10−6 m and H) 0.01 × 10−6–9 × 10−6 m. Reproduced with permission.89 Copyright 2011, American Chemical Society.

While other approaches, such as the change of LSPR induced by surface reduction and competitive binding between S‐Au and I‐Au (forming clusters or larger nanoparticles),80, 81 have been used with gold‐based sensors, the sensing limits only reach about 0.3 × 10−6 m for H2S detection. Comparably, catalysis mediated by Au based nanosensors has excellent sensitivity.83, 85 A catalysis Au@TPt‐NCs (Au core with an ultrathin platinum shell) nanoplatform was developed by Gao et al. to detect dissolved H2S gas (Figure 2B).85 The H2S evaporated or dissolved interacts with and deactivates the nanoclusters, attenuating the chromogenic reaction between H2O2 and 3,3′,5,5′‐tetramethylbenzidine (TMB) and showing an extremely low LOD value at 7.5 × 10−9 m. More importantly, the approach is also visible to the naked, providing flexibility for applications (Figure 2C,D).

Additionally, the Au/Ag alloy has also been recruited for sensing H2S by fluorescence quenching.86, 87 Among all, a sensitive DNA‐templated Au/Ag NCs was successfully developed by Chen et al (Figure 2E,F).87 In the presence of H2S, the prepared Au/Ag NCs showed a linear relationship (0 × 10−6–0.01 × 10−6 m and 0.01 × 10−6–9 × 10−6 m) between the H2S concentration and fluorescence intensity, with a quantum yield of 4.5% and a LOD of 0.83 × 10−9 m (Figure 2G,H). Among Ag‐based nanoplatforms, only several polymer‐coating Ag nanoparticles have been investigated and relatively‐low efficiency was demonstrated for H2S detection (0.2 × 10−6–3.3 × 10−6 m) compared with that provided by Au‐based nanoprobes.42, 43, 88

3.2. Metal‐Organic Framework (MOF)

The past decade has seen drawn a great deal of attention to metal‐organic framework (MOF) due to their excellent physiochemical features.105, 106, 107, 108, 109, 110 These nanomaterials are composed of different combinations of metal ions, organic linkers, and modifications and have vast application possibilities (e.g., gas storage, chemical sensing, chiral separations, etc.).111 With the tremendous surface area (≈7000 m2 g−1) and rigid pores that could host various functional molecules, MOF has also been investigated as a potential sensor for chemical and toxic gas detection, such as hydrosulfide.112 Through the formation of the metal sulfides (e.g., CuS),46, 89, 90 amine group,39 or N—S bond91 with S2−, several novel MOFs could recover the fluorescence/luminescence that was quenched and trigger a detectable signal for sensing H2S with a desirable sensitivity. For instance, the presence of Tb3+/Cu2+ ions enables the Tb3+@Cu1/Cu2 MOF complex to generate multiwavelength luminescence and produce an enhanced ratiometric signal (I 544/I 390) after the interaction with the H2S exposed, with a LOD of S2− at about 1.2 × 10−6 m.89 Similarly, Qian Lab synthesized an Eu3+@UiO‐66‐(COOH)2 MOF that induced a fluorescent signal via the interaction between Cu2+ and S2−.46 Although such MOF exhibits a uniform nanostructure (80–100 nm) and comparable H2S LOD (5.45 × 10−6 m), the fluorescence intensity generated could be affected by amino acids containing thiol and nitroxyl groups, which strongly lowers selectivity toward H2S.46 Comparably, the novel sensors, Zr(TBAPy)5(TCPP) and aluminum‐based MOF (Al‐MIL‐53‐NO2) demonstrate desirable H2S detection and selectivity via reduction, with LOD of ≈92.31 × 10−9 m and ≈1 ppb, respectively.39, 91 The Zr(TBAPy)5(TCPP) were synthesized with a uniform nanostructure (with a diameter around 100 nm) after incorporation of Tris(2‐chloroisopropyl)phosphate (TCPP) (Figure 3 A,B).91 This synthesized nanoparticle was very sensitive to H2S (with a LOD around 50 × 10−9 m), and only showed fluorescence after the introduction of H2S, demonstrating a desirable linear relation between fluorescence and the concentration of H2S (Figure 3C,D,F). More importantly, the reaction of Zr(TBAPy)5(TCPP) and H2S was completed within 10 s, providing an opportunity for real‐time detection (Figure 3E).

Figure 3.

Figure 3

A) Representative TEM and B) HR‐TEM images of Zr(TBAPy)5(TCPP); C) The photoluminescence emission spectra among Zr(TBAPy)5(TCPP) (black), NU‐1000 (red), TBAPy (blue), and TCPP (cyan). D) The variation of fluorescence generated by Zr(TBAPy)5(TCPP) with a series of S2− concentrations and E) the change of fluorescence intensity at various time points post the addition of S2− into the Zr(TBAPy)5(TCPP) solution; F) Fluorescence pictures (λex = 365 nm) of Zr(TBAPy)5(TCPP) aqueous solutions with different anions. Reproduced with permission.93 Copyright 2018, Wiley.

As alternatives to single substrate MOFs, probes for the detection of multiple biomolecules are highly desirable for large scale detection in environmental or clinical assay. Recently, a Eu3+‐Cu2+ based MOF was developed.90 With two specific and separate binding areas for ascorbic acid (AA) and H2S, it simultaneously detected both biomolecules. Due to the high sensitivities, the as‐prepared MOF can identify H2S and AA concentrations as lower as 130 × 10−9 and 55 × 10−9 m, respectively. Additionally, desirable recovery rate (94.7–104.1%) was attained in assays using human serum. After incorporating various elements and molecules, novel MOF‐based probes for multiple biomolecule detection have significant promise for biomedical applications.

3.3. Copper Based Nanomaterials

Copper (Cu), the most‐used cation for H2S sensing (via the metal precipitation), has been widely incorporated into small organic molecules (e.g., HSIP‐1) and the other nanosized probes.78, 80 The addition of Cu to nanomaterials in the form of Cu, CuO, or Cu2O is also employed for H2S‐specific detection.52 Coating the surface of nanoparticle sensors (e.g., nanowires, nanoneedles, or nanotubes) with Cu, CuO, or Cu2O enables rapid detection of H2S due to variations in conductivity after reduction. As such, the concentration of H2S in the solution or air can be determined.53, 92, 93 For example, a Cu2O NPs (2–3 nm) coated WO3 nanoneedles were prepared via aerosol‐assisted chemical vapor deposition (AACVD).53 This system was able to detect H2S levels as low as 300 ppb within two seconds. A major limitation of the Cu2O‐WO3 nanoneedles was the high temperature required (390 °C) that makes practical application difficult. A Quasi‐2D‐Cu2O/SnO2 consisting of P‐type Cu2O and N‐type SnO2 was successfully developed for H2S gas detection at room temperature, with a LOD at 0.5 ppm.94 Notably, laser illumination further reduced the heterojunction barrier and enhanced the response of Quasi‐2D‐Cu2O/SnO2 by 20%. The Chen lab synthesized a Cu2O‐FGS (functional graphene sheets) by in situ growth that provided desirable surface accessibility, contacting area (Cu2O was prepared without surfactant) and sensitivity (LOD is around 5 ppb) for H2S gas sensing under normal atmospheric conditions (Figure 4 A–C).52

Figure 4.

Figure 4

A) Schematic demonstrating the in situ approach for synthesizing the Cu2O‐FGS (functional graphene sheets) platform; B) Representative SEM image of the Cu2O–FGS established on the Si/SiO2 substrate with gold interdigitated electrodes coverage; C) Sensitivity limits of Cu2O–FGS and FGS based detector in series of concentrations of atmospheric H2S. Reproduced with permission.52 Copyright 2013, Royal Society of Chemistry. D) Schematic illustration of the polystyrene sulfonate (PSS) mediated PSS‐PAE‐Cu NC synthesis. E) Optical images of PSS‐PAE‐Cu NC aggregates prepared via various concentrations of PSS (0.005–0.5 wt%) without (upper row) and with UV illumination; F) The photoluminescence spectra of the PSS‐PAE‐Cu NC aggregates under various concentrations of H2S and the linear relationship between the photoluminescent intensity of PSS‐PAE‐Cu NC aggregates and the concentration of H2S with sodium phosphate buffer (10 × 10−3 m, pH 3.0). Reproduced with permission.97 Copyright 2016, Nature Research.

Several studies have confirmed that the aggregation of organic Cu NCs (e.g., cysteine or penicillamine (PAE) template) can activate an enhanced fluorescence referred to as aggregation‐induced emission (AIE).95, 96 By incorporating polystyrene sulfonate (PSS) into the system, PSS‐PAE‐Cu NCs aggregates were designed H2S detection in drinking water (Figure 4D).95 With the 0.05 wt% PSS, as‐prepared PSS‐PAE‐Cu NCs aggregates (173 nm) generated red photoluminescence (665 nm) that was extinguished when as little as 650 × 10−9 m H2S was present (Figure 4E,F).

3.4. Carbon Nanodot

Since the first discovery at 2004, carbon nanodots (C‐dots or CDs) have been widely investigated for biomedical, catalytic, and sensing applications due to its attractive features of high solubility, biocompatibility, and photostability.113, 114, 115 Among all, several novel C‐dots have been designed for H2S detection/imaging.51, 97, 116, 117 For example, two metal ion (Ag+/Hg+) based C‐dots were synthesized for sensing sulfide ions. In the presence of H2S as low as 0.32 × 10−6 and 0.43 × 10−6 m respectively, the fluorescence of CD‐Hg+/Ag+ would be quenched by the inner filter effect (IFE) mediated by the Hg2S/Ag2S formed. Meanwhile, the formation of Ag2S significantly changes the Ag–C‐dot's electrochemiluminescence that shows a desirable sensitivity with a LOD at 27 × 10−9 m.56, 57

3.5. Other Nanosensors

Other nanomaterials such as Pb‐based NPs, graphene supporting and polymeric nanocomposites, and ruthenium NPs have been investigated as nanosensors for H2S detection (Table 2).44, 98, 99, 100, 101, 102, 103 Given the great conductivity of graphene, a SnO2‐rGO (reduced graphene oxide) nanosheet was successfully developed via a one‐step colloidal synthesis for H2S sensing (Figure 5 A).100 H2S gas was adsorbed (i.e., chemisorption) and detected within 2 s at room temperature with a desirable sensitivity (with LOD at 43 ppb) (Figure 5B,C). Two polymeric nanoparticles, the PPy/WO3 (50–70 nm) and cyclen‐FPNs (33–40 nm) were designed for identifying this gas as well.99, 101 After electrochemical electron transfer (i.e., H2S + 3O2 → 2H2O + 2SO2 + 3e) and the formation of CuS (i.e., the recovery of fluorescence), H2S concentrations could be well determined by PPy/WO3 and cyclen‐FPNs (Table 2). Recently, Zhao et al. developed a colorimetric approach via the catalysts mediated by ruthenium nanoparticles (Ru NPs) (Figure 5D).44 The synthesized Ru NPs (1.7 ± 0.2 nm) degraded the organic dye—Orange I. The resulting color fade occured about 4, 47, and 165 times faster than for platinum (Pt), iridium (Ir) based NPs, and control groups. Exposure of the Ru NPs and Orange I to H2S protected the Orange I by deactivating Ru NPs (Figure 5E). The superior catalytic capability of Ru NPs demonstrated an excellent LOD (about 0.6 × 10−9 m), but it had a relatively poor selectivity to H2S as cross‐reaction with Cys and GSH occurred (Figure 5F).44

Figure 5.

Figure 5

A) Representative HR‐TEM images of SnO2/rGO nanocomposites and the electron diffraction pattern within the selected area. B) The selective capability of SnO2/rGO nanocomposites for detecting H2S gas among various interference. C) The response rate of SnO2/rGO nanocomposites under different H2S gas concentrations. Reproduced with permission.102 Copyright 2016, American Chemical Society. D) Schematic demonstrating the Ru NPs‐based colorimetric assay for H2S detection via the hydrogenation catalysis. E) The change of constant rate under various concentrations of Na2S (5 × 10−9–100 × 10−9 m), the H2S donor. F) The different absorbance intensities (512 nm) of Ru‐NPs and orange I mixtures with various biological thiols and other amino acids attendance, and corresponding optical images of samples within 2 min (inserted figure). Reproduced with permission.44 Copyright 2017, American Chemical Society.

4. H2S Imaging with SHTS‐Based Nanomedicine

As we have mentioned, micro‐ or nano‐probes have been widely applied for H2S measurements in clinical samples and has greatly facilitated bench efforts. However, the real‐time imaging of H2S secretion in patients for disease diagnosis, especially tumor tracking, is still highly demanded. Among all the in vitro and in vivo imaging candidates, nanocarriers have shown great potential as fluorescent, LSPR, upconversion luminescence (UCL), near infrared (NIR), photoacoustic (PA) and positron emission tomography (PET) imaging probes (Table 3 ). In comparison with the fluorescence and UCL imaging, only a few of nanoprobes has been used for H2S imaging via NIR, LSRP, PA, and PET. These nanosensors would be described in detail in this section.

Table 3.

The novel nanosensors as SHTS for H2S imaging

Imaging strategy a) Material Nanoparticles Size [nm] Mechanism Assay Sample(s) LOD Ref.
FL MOF UiO‐66‐CH = CH2 20–30 Reduction (C = C) Em ≈ 370 PC‐12 cell 6.46 × 10−6 m 120
[Al(OH)(IPA‐N3)]·3.2 H2O·0.4DMF N/A Reduction Em405 J774A.1 cell 2.65 × 10−6 m 121
CuO@TO@UiO‐66 N/A FRET interruption (Turn‐off) Em520‐650 A549 and HepG2 cell 0.51 × 10−6 m 45
C‐dot C‐Dot‐Ligand‐Cu2+ ≈5 Metal precipitation Em455 HeLa and L929 cell 0.78 × 10−6 m 117
C‐Dot‐TPEA–Cu2+ ≈5 Metal precipitation Em560 Hela cell and A549 tumor slide 0.7 × 10−6 m 116
Cyclam‐CDs (CCDs) ≈2 Metal precipitation Em460 Hela cell 130 × 10−9 m 122
FCDs‐Cu2+ 4 Metal precipitation Em452 Hela cell 88.9 × 10−9 m 40
CD‐based sensor ≈5 FRET induction (Turn‐on) I526/I425 HeLa and L929 cell 10 × 10−9 m 50
Other FAM‐DNA/AgNP 10 ± 3 Reduction Em520 Hela cell 10 × 10−9 m 47
NanoBODIPY ≈10 FRET interruption (Turn‐on) Em589 Raw 264.7 cell 7 × 10−9 m 49
LSPR Au/Ag Au/Ag PNPs 74.19 LSPR shift A702 (Dark field imaging) HepG2 and Hela cell 0.1 × 10−6 m 41
UCL UCNPs Cy7‐UCNPs 11.27–44.6 LRET interruption (Turn‐on) Em800 Hela and MCF‐7 cell; Zebra fish 510 × 10−9 m 123
TPAMC‐UCNPs@PEG ≈35 LRET interruption (Turn‐on) I530/I660 Hela and MCF‐7; HCT‐116 bearing mice 0.22 × 10−6 m 48
NaYF4: 20% Yb, 2% Er, 0.2% Tm 94 LRET interruption (Turn‐on) Igreen/Ired Hela cell 0.58 × 10−6 m 124
CHC1‐UCNPs 24 LRET interruption (Turn‐on) I 541/I 800 Hela cell and Mice (LPS) 0.13 × 10−6 m 125
PAA‐NaYF 4:Yb/Er/Tm 12 LRET interruption (Turn‐on) I540/I800 or I650/I800 Hela cell N/A 34
NIR Silica ZX‐NIR ≈66 Nucleophilic substitution Em900‐1300 HepG2, HCT‐116 cell and tumor‐bearing mice ≈37 × 10−9 m 126
PA Silica Si@BODPA180 ≈75 Nucleophilic substitution ex780 HCT‐116 bearing mice 53 × 10−9 m 38
Liposome AzHD‐LP ≈12 Reduction ex700 HCT‐116 cells and HCT‐116 bearing mice 91 × 10−9 m 127
PET 64Cu2+ 64Cu‐cyclen N/A Metal precipitation PET Mice and Rat 0.15 × 10−6 m (≈1% g−1) 128
a)

FL: fluorescence; UCL: Upconversion luminescence; NIR: Near infrared; PA: photoacoustic imaging; PET: positron emission tomography.

4.1. Fluorescence Imaging

With the innovation of imaging technology, two‐ and multiphoton microscopy has been used for fluorescence imaging, which greatly improved the depth of penetration (≈1 mm).118, 119 However, most fluorescent agents have generally employed for living cell or tissue section based imaging. For instance, the incorporation of organic components (azide or unsaturated C=C bond) enabled MOF to be used for specific imaging in a series of cancer cell lines (e.g., PC12 and J774A.1 cells) via reduction mediated by H2S.120, 121 Comparably, further functionalization with Cu2+ based ligands (e.g., Cyclam‐Cu2+) enabled the C‐Dots to visualize H2S within cells via fluorescence initiated after CuS precipitation.40, 116, 117, 122 These nanosensors demonstrated desirable biocompatibility and efficiently detected H2S in Hela or L929 cells, with LOD ranging from around 90 × 10−9–780 × 10−9 m. Notably, C‐Dot‐TPEA–Cu2+, a two‐photon nanoprobe, exhibited excellent tumor penetration that could be used for sensing H2S in A549 tumor sections. This system provided an emission wavelength (560 nm) suitable to minimize background for H2S and nuclei imaging, compared with those (≈460 nm) offered by other C‐dots.116

Internal Förster resonance energy transfer (FRET) is able to aid specific imaging of H2S in vivo. The FRET acceptor (e.g., CuO coated on the surface) or probe structure changes could initiate or terminate FRET in response to H2S.45, 49, 50 Notably, carried fluorophores can change its excitation or emission wavelength to act as the imaging trigger when exposed to H2S.49 For instance, boron‐dipyrromethene (BODIPY), with a small Stokes shift and high fluorescent quantum yields, has been widely employed in various nanosized platforms for probing H2S. A micellar nanomaterial was designed by incorporating an amphiphilic copolymer (mPEGDSPE), semi‐cyanine‐BODIPY hybrid dye (BODInDCI), and BODIPY1 as the energy donor for H2S imaging. (Figure 6 A).49 Once the BODInDCl was exposed to H2S, its absorption wavelength rapidly shifted from 540 to 738 nm and suspend FRET between it and BODIPY1, eventually recovering and switching off fluorescence at 511 and 589 nm (Figure 6B). Importantly, this reaction was quickly finished within 140 s, demonstrating high efficiency for H2S detection.129 Additionally, this nanoBODIPY probe was able to track endogenous H2S in a macrophage cell line (RAW 264.7) based on the ratio between the dual‐color images (Figure 6C,D).49

Figure 6.

Figure 6

A) Schematic interpretation of FRET between the responsive energy acceptor (BODInD‐Cl, red star) and the complementary energy donor (BODIPY1, green star) in the NanoBODIPY micellar aggregate. B) The fluorescence spectra of the NanoBODIPY under different concentrations of NaHS (0 × 10−6 to 10.0 × 10−6 m); confocal microscopy images detecting H2S within live macrophage cells (Raw 264.7) using NanoBODIPY. C) 30 min incubation of cells and NanoBODIPY (top row) and 30 min incubation of the cells pretreated with 2.0 × 10−6 m fluvastatin (the CSE stimulator) for 48 h and NanoBODIPY (bottom row). D) 30 min incubation cells and NanoBODIPY followed by 100 × 10−6 m NaHS (top row) and 30 min incubation of the cells pretreated with 1 × 10−3 m DL‐propargylglycine (PAG, the CSE inhibitor) for 1 h along with 2.0 × 10−6 m fluvastatin (the CSE stimulator) for 48 h and NanoBODIPY (bottom row); ratio images were generated for the green channel (500–550 nm) relative to the red channel (560–650 nm). Reproduced with permission.49 Copyright 2016, American Chemical Society.

4.2. LSPR Dark‐Field Imaging

Plasmonic nanoparticles (PNPs), such as gold nanorods (AuNR), can provide extremely bright signal compared with organic fluorescent dyes.130, 131 By further coating Ag on the AuNR, Xiong et al. successfully applied the gold nanorod‐silver (AuNR‐Ag) core–shell PNPs for mapping H2S n living cells via dark‐field imaging.41 The AuNR‐Ag PNP (74 × 19 nm core and 2.1 nm shell) generated Ag2S and changed its LSPR wavelength when it encountered with H2S (Figure 7 A,B). Notably, a linear logarithmic was observed between the spectral shifts and sulfide concentrations (ranging from 0.01 nm to 10 × 10−6 m) at various time points (1–30 min), indicating extremely high sensitivity. In addition, the AuNR‐Ag PNP demonstrated excellent H2S selectivity compared to other inorganic sulfur ions. Using this nanoplatform, the fluctuations of sulfide (0 × 10−9–100 × 10−9 m) and real‐time H2S mapping/calculation around single AuNR‐Ag PNP within live cells (from 5.8 × 10−9–41.8 × 10−9 m or 0.5 × 10−9–3.8 × 10−9 m for P1 or P2 respectively) was successfully achieved (Figure 7C–E).

Figure 7.

Figure 7

A) TEM and HR‐TEM images of AuNR‐Ag nanoprobes consisting of a AuNR core and Ag shell. B) The LSPR spectra of AuNR (green), AuNR‐Ag (purple), and AuNR‐Ag2S (red) nanoparticles via the experimental (left) and discrete dipole approximation (DDA) simulated approaches (right). The representative dark‐field images of two individual PNPs in different time points at C) 2 min, D) 26 min, and E) 42 min after the addition of 0.1 × 10−3 m Na2S into the HepG2 cells. The length of the scale bar is 10 mm. The individual PNPs are enlarged and presented in the inserted squares. Reproduced with permission.41 Copyright 2013, Nature Research.

4.3. UCL Imaging

Upconversion nanoparticles (UCNPs) convert continuous‐wave (CW) NIR wavelengths to visible light with a sizeable anti‐Stokes shift of several hundred nanometers.132, 133, 134, 135, 136, 137 Compared to organic dyes and inorganic semiconductor nanoparticles, UCNPs display superior features, such as scarcely autofluorescence from biological samples,138 a remarkable light penetration depth (up to 10 mm),139 no photobleaching in bioapplications,140, 141 and less damage to biological samples than UV excitation source.142 As a result, UCNPs are ideal probes for visualizing living cells and whole‐body animals.143, 144, 145 To achieve a sensing function, UCNPs need to combine with other chromophores with recognition sites, through the luminescence resonance energy transfer (LRET) process. Several UCNPs‐chromophores based LRET nanosystems have been developed for detecting critical biological species and toxins, such as DNA, O2, CN, Hg2+, and Zn2+.146, 147, 148, 149, 150 In these applications, the UCNPs (donor) transfer energy to the organic chromophores (acceptor) and results in changes to the UCL emission. Thus, UCNPschromophores are excellent candidates for H2S sensing probes.

Since the multicolor luminescence of UCNPs can be tuned by doping different ions, a series of chromophores with different absorption bands could be combined and designed for H2S‐specific response. For example, Peng et al. compared three H2S‐responsive chromophores combined with different doping ions UCNPs (NaYF4:Yb/Er/Tm, NaYF4:Yb/Er/Mn). This library of H2S sensors had responsive emission signals ranging from the visible to the NIR region.34 These UCNPs‐chromophores showed various LRET efficiency (11.8–25.1%), but all exhibited high excellent selectivity and rapid responsiveness in live cells and blood serum. Doping Tm3+ into UCNPs introduces UCL signals at 800 nm that can be utilized as an internal standard for ratiometric detection of H2S to improve sensitivity. As an example, Liu et al. employed NaYF4:20%Yb,2%Er,0.2%Tm@mSiO2‐merocyanines for ratiometric detection of H2S using multiwavelength UCL.151 UCNPs@mSiO2‐MC showed an enhanced ratiometric signal (I 540/I 800) for higher sensitivity with LOD at ≈0.58 × 10−6 m, which was lower than that of another merocyanine‐based H2S probe (1.0 × 10−6 m).152 Similarly, Zhou et al. used NaYF4:20%Yb,1.8%Er,0.5%Tm@α‐cyclodextrin (CD)–coumarin hemicyanine (CHC1) dye as a ratiometric UCL probe (Figure 8 A).153 By measuring the ratio of I 580/I 800, this UCNPs was able to measure H2S concentrations as low as 0.13 µm, much more sensitive than single UCL signals (1.85 µm) in aqueous solution (Figure 8B). This UCNPs@CD‐CHC1 could be used for ratiometric UCL monitoring of pseudo‐enzymatic H2S production in living cells, and also showed for ability to detect lipopolysaccharide (LPS)‐induced inflammation in the liver tissues of mouse models for the first time (Figure 8C).

Figure 8.

Figure 8

A) Schematic demonstrating the LRET process between the energy acceptor (CHC1) and energy donor (UCNPs). B) The change of CHC1‐UCNPs' UCL emission patterns under a series of H2S concentrations (0 × 10−6–90 × 10−6 m), and the ratiometric values (I 541/I 800) along with optical image of green UCL emission are presented as inserted figure and photo. C) The UCL imaging of H2S expressed endogenously in mouse liver: a) the in vivo UCL imaging of the mice with inflammatory (for 24 h) after intravenous injection with CHC1‐UCNPs; b–d) The UCL images of liver section obtained from the mice injected with PBS and CHC1‐UCNPs only; e–g) The UCL images of liver section harvested from the mice administrated with LPS (20 mg kg−1) and CHC1‐UCNPs; h) The average UCL ratiometric values among different tissues. Images were acquired under an excitation 980 nm, with a green channel around 500–560 nm and red channel at 600–700 nm. Reproduced with permission.153 Copyright 2014, Wiley.

UCNPs have also been developed for detecting or imaging of small molecules, biomacromolecules, organs, and tumors. Li et al. developed a merocyanine derivative modified UCNPs (NaYF4: 20%Yb, 2%Er, 0.2%Tm)@PEG as a ratiometric UCL probe for H2S detection in mitochondria of live cells and live‐tissues (Figure 9 A–C).154 This probe was used for locating the HCT116 (human colorectal cancer cell line) tumor in vivo by using NIR UCL imaging (Figure 9D–F). Additionally, this system was capable of monitoring mitochondrial H2S within tumor slices via a ratiometric UCL measurement (Figure 9G).

Figure 9.

Figure 9

A) Schematic of the cellular targeting process and mitochondrial H2S detection mediated by the TPAMC‐UCNPs@PEG nanoplatform. B) Schematic of the LRET mechanism between UCNPs and TPAMC with or without H2S. C) The chemical structures of TPAMC and TPAMC‐SH. D) The UCL imaging obtained from HCT116 tumor‐bearing mice post‐intravenous administration of TPAMC‐UCNPs@PEG. E) The ex vivo UCL images and F) the corresponding fluorescence quantifications of the major organs at 24 h post the TPAMC‐UCNPs@PEG injection (n = 3). G) The two single channels and ratiometric UCL images of the tumor sections from the mice intravenously administrated with TPAMC‐UCNPs@PEG and further injected with PBS (top raw) and S‐adenosyl‐l‐methionine (SAM) (button raw). The green (500–560 nm) and red (600–680 nm) signal of UCL were obtained under a 980 nm excitation. Reproduced with permission.156 Copyright 2018, American Chemical Society.

To monitor H2S using UCL imaging both ex vivo and in vivo, Wang et al. proposed a PAA‐UCNPs (NaYF4:Yb/Tm@NaYF4) loaded with a cyanine chromophore (Cy7‐Cl) as a NIR probe for H2S response. (Figure 10 A).155 This nanoprobe was able to emit luminescence at 800 nm (Figure 10B,C) and demonstrated superb sensitivity toward H2S (Figure 10D,E). In addition to imaging exogenous and endogenous H2S in living cells (Hela and MCF‐7 cells), the Cy7‐UCNPs were successfully employed for sensing H2S in tumor‐bearing zebrafish in real time, with high penetration depth and low autofluorescence background (Figure 10F,G). Thus, the UCNPs‐chromophores were capable of monitoring H2S in living cells and small animals by UCL imaging. Ratiometric UCL‐based nanosystems provide a new design strategy for sensing and imaging of H2S that might be further utilized by novel probes for highly sensitive in vivo imaging studies.

Figure 10.

Figure 10

A) Schematic of luminescent strategy employed by PAA‐UCNPs, and the chemical structures of Cy7‐Cl and Cy7‐SH. B) The luminescence spectra of PAA‐UCNPs, Cy7‐UCNPs, and Cy7‐UCNPs + Na2S (50  × 10−6 m). C) The UV–vis absorption spectra of Cy7‐Cl (black) along with Cy7‐Cl + Na2S (blue), and the UCNPs' luminescence spectrum (red). D) The change of luminescence spectra upon the addition of various Na2S concentrations (0 × 10−6–100  × 10−6 m). E) The enhancement of fluorescence ratio accompanied by increasing concentrations of Na2S. F) In vivo UCL images of exogenous and endogenous H2S in zebrafish via the Cy7‐UCNPs imaging system: a,b) normal zebrafish were injected with PBS, followed by an administration of Cy7‐UCNPs 30 min later; c,d) tumor‐bearing zebrafish was administrated with PBS, followed by an injection of Cy7‐UCNPs 30 min later; e,f) tumor‐bearing zebrafish was first injected with NMM (the scavenger of intracellular H2S), followed by an injection of Cy7‐UCNPs 30 min later; g,h) tumor‐bearing zebrafish was administrated with l‐Cys (the precursor of H2S), followed by the administration of Cy7‐UCNPs 30 min later; the length of scale bar is 500 µm. G) The corresponding average UCL intensities of data in (a,c,e,g). Reproduced with permission.157 Copyright 2018, Elsevier.

4.4. NIR Imaging

Various fluorescent probes have been successfully employed for detection of cellular H2S. However, most of these fluorescent probes emit in the ultraviolet or visible light region (450–750 nm that is impeded by cell autofluorescence. In contrast, long wavelength probes with emission in the NIR region are optimal for biological imaging applications due to minimal photodamage to biological samples and interference from background autofluorescence in living systems.156, 157 Additionally, NIR light (700–900 nm) can well improve the tissue depth penetration for in vivo imaging.158, 159 Among NIR fluorochromes, cyanine dyes have excellent photophysical properties, such as outstanding biocompatibility and low toxicity to living systems, which is suitable incorporation as a fluorescent probe.159, 160 For example, Wang et al. designed a NIR fluorescent cyanine probe Cy–NO2 (em. ≈789 nm) for H2S detection (via nitro group reduction) in aqueous solution and living cells.161 Similarly, Zhang et al. reported a cyanine‐based NIR probe (em. ≈796 nm) for a highly sensitive (with LOD at 39.6 × 10−9 m) and selective imaging of endogenous H2S in tissues and tumor models (HCT116 and HT29) of mice.162

Recent progress has demonstrated that fluorescence imaging in the second near‐infrared window (NIR‐II, 1000–1700 nm) can further improve image contrast at increased tissue depths. Moreover, NIR‐II fluorescence imaging remarkably reduces interference from photon absorption and displays higher in vivo spatial resolution than NIR‐I imaging.163 Zhao's group fabricated an H2S‐triggered NIR‐II nanoprobe for visualizing colorectal cancers (Figure 11 A).164 The nanoprobes were comprised of a silica shield and two organic chromophores, a boron‐dipyrromethene dye generating the NIR‐II emission (em. 900–1300 nm) with the presence of H2S and an inert aza‐BODIPY dye (em. 700 nm) as the internal reference (Figure 11B,C). The NIR‐II@Si showed a selective identification of H2S rich colon cancer cells via a dual color imaging modality (Figure 11D,F,G). Moreover, NIR‐II@Si was further explored for the H2S‐triggered NIR‐II imaging with the supporting of SAM (S‐adenosyl‐l‐methionine, the CBS activator) (HCT‐116 tumors), showing enhanced deep tissue penetration and spatial resolution (Figure 11E).164

Figure 11.

Figure 11

A) Schematic of the formation of NIR‐II@Si nanoprobe and the chemical structures of components including ZX‐NIR and NIRII‐HS. B) The variation of NIR‐II spectra of as‐prepared NIR‐II@Si at different time points after the addition of 100 × 10−3 m NaHS, and the NIR‐II images of NIR‐II@Si after H2S activation (10 mm ZXNIR) in the presence of 100 mm NaHS (inserted photo). C) The NIR‐I and NIR‐II fluorescent images of the H2S‐activated NIR‐II@Si covered by pork skin with various thicknesses. The NIR‐I and NIR‐II imaging of the D) HCT116 tumor, G) HepG2 tumor, and F) normal tissue from tumor‐bearing mice or normal mice at different time points (5, 15, and 30 min) after intratumor or on‐site injection of NIR‐II@Si nanoprobe. E) The NIR‐II images of HCT‐116 tumor‐bearing mice at 5, 15, and 30 min postinjection of NIR‐II@Si nanoprobe along with AOAA (amino‐oxyacetic acid, the inhibitor) or SAM (S‐adenosyl‐l‐methionine, the activator). Reproduced with permission.166 Copyright 2018, Wiley.

4.5. PA Imaging

Among imaging methods that are not fluorescence‐based, PA imaging is a newly emerging technique. This modality is based on the PA effect of translation of excitation light into ultrasonic waves, which bridges the traditional depth and resolution limits of conventional optical imaging techniques.165, 166 As the acoustic waves are generated by pulsed laser light, noninvasive biomedical images with sharp optical absorption contrast and high ultrasonic resolution are produced.167, 168 The development of chemical PA probes proposed a new perspective for monitoring therapeutic response and real‐time molecular imaging.169, 170 For H2S detection, Shi et al. first presented a PA probe by encapsulating semi‐cyanine‐BODIPY hybrid dyes into the core–shell silica nanocomposites (Si@BODPA), enabling real‐time imaging of H2S‐related biological processes (Figure 12 A).171 Based on the thiol‐halogen nucleophilic substitution reaction, the Si@BODPA produced emission at 780 nm after the hydrogen sulfide activation, leading to a 44‐fold turn‐on response within 15 s (Figure 12B,C). The LOD was determined to be as low as 53 × 10−9 m, a sufficient sensitivity for detecting endogenous H2S within living systems. Due to its rapid response, Si@BODPA was then employed for the real‐time monitoring of endogenous H2S generation in HCT116 tumor‐bearing mouse to verify elevated level of H2S due to CBS upregulation (Figure 12D).

Figure 12.

Figure 12

A) Schematic of the Si@BODPA nanoprobe. B) The change of absorbance of the Si@BODPA1 along with Si@BODPA2 with and without NaHS (100 × 10−3 m). C) The reaction times among BODPA2‐Si@BODPA30 (13 min), BODPA2‐Si@BODPA90 (6 min), BODPA1‐Si@BODPA30 (5 min), BODPA1‐Si@BODPA90 (2 min), BODPA1/2‐Si@BODPA180/270 (within 15 s), and H2S (100 × 10−3 m). D) In vivo photoacoustic images of the mice bearing HCT‐116 tumor via the subcutaneously‐injected BODPA1‐Si@BODPA180: a) the tumor regions with saline injection; b) the normal area with nanoprobe injection; c) the tumor regions with nanoprobe administration; d) the tumor area from the pretreated mice (100 nmol AOAA, 12 h in advanced) with nanoprobe administration; e) the tumor area from the pretreated mice (300 nmol SAM, 12 h in advanced) with nanoprobe injection; f) the corresponding PA intensities in a series of time points post BODPA1‐Si@BODPA180 injection. Reproduced with permission.173 Copyright 2017, Royal Society of Chemistry.

Ratiometric PA probes are able to further eliminate some of the shortcomings of a single responsive PA signal by self‐calibration. Thus, the combination of two PA responsive signals at two separated wavelengths would efficiently improve the accuracy of results. For example, Ma et al. developed a ratiometric photoacoustic nanoprobe AzHD (H2S‐responsive NIR dye) that was carried by a liposome for monitoring and imaging of H2S in cells, brain tissues, and live mice.127 With H2S‐mediated reduction of the azide, the AzHD‐LP absorption centered at 600 nm gradually decreased, and a new absorption band at 700 nm subsequently appeared (Figure 13 A). Through this design, the ratio of PA700/PA532 increased about 4.5‐fold after reactive with H2S, which was about 23‐fold higher than a single PA signal alone (Figure 13B,C). The LOD of ratiometric PA signals was determined to be 91 × 10−9 m. This enabled the ratio of PA700/PA532 PA signal of healthy and Alzheimer's disease (AD) mice brains (homogenate supernatant) to increase by 6.5 and 1.2‐fold, respectively, following AzHD‐LP introduction (Figure 13D,E). Additionally, further conjugating the RGD targeting group to the AzHD‐LP allowed for successful monitoring of H2S in the HCT116 tumor‐bearing mice using time‐dependent dual‐channel ratiometric PA signals (Figure 13F–I). Therefore, the newly designed ratiometric PA probes of H2S sensing system provides a powerful analytical and imaging tool for further exploration of the roles of H2S in living complex organisms.

Figure 13.

Figure 13

A) Schematic of the ratiometric photoacoustic AzHD‐LP system, the change of the AzHD chemical structures, and PA absorbance (decrease of 532 nm and enhancement of 700 nm) after H2S exposure. B) The variation of two PA intensity (532 and 700 nm) of AzHD‐LP under different NaSH concentrations. C) The enhancement of PA700/PA532 ratio with increasing concentration of NaSH. D) The optical images of brain tissue from the normal mice and the mice with Alzheimer's Disease (AD). E) The plot of the PA700/PA532 ratio obtained from the AzHD‐LP after incubation with the brain homogenates from normal or AD mice. F) Schematic of the formation of RGD‐AzHD‐LP. G) The overlayed imaging of PA (PA700 and PA532) or ratiometric PA (PA700/PA532) with ultrasound acquired from the mice bearing subcutaneous HCT116 tumor. H) The corresponding quantitative intensity plot of PA532 (green) and PA700 (red) in (G). I) The ratiometric intensity of PA700/PA532 obtained from different groups at four hours post the intravenous administration of RGD‐AzHD‐LP: a) 12‐hour preinjection of PBS in the tumor area; b) 12‐hour preinjection of SAM (300 nmol) in the tumor area; c) 12‐hour preinjection of AOAA (100 nmol) in the tumor area; d) 12‐hour preinjection of ZnCl2 (H2S trapper) in the tumor area; the length of scale bar is 5 mm. Reproduced with permission.129 Copyright 2018, Royal Society of Chemistry.

4.6. PET Imaging

Although fluorescence‐based imaging techniques are primarily utilized for H2S detection, their applications in live‐animal imaging are limited because of the limited quantitative analysis. PET provides a highly sensitive non‐invasive technology for molecular imaging assays of metabolism, signal transduction, and gene expression from mice to patients.172, 173, 174 Unsurprisingly, targeted and sensitive PET probes have also been developed for H2S imaging. As an example, Yoo's group utilized 64CuS nanoparticles for the detection, quantification, and in vivo imaging of endogenous H2S via PET imaging.128 These nanoparticles were formed by twenty macrocyclic 64Cu complexes reacting with gaseous H2S to form insoluble 64CuS (Figure 14 A). 64Cu‐cyclen showed high sensitivity (with a LOD at 0.15 µm) and selectivity for H2S over other potential competitors, including polysulfides. Due to the physical differences, the intravenously injected 64Cu‐cyclen and 64Cu‐cyclam were quickly cleared from the body, while the insoluble 64CuS nanoparticles were immobilized for more than 4 h after encountering H2S (Figure 14B). When 64Cu‐cyclen was administrated into mice intravenously, an elevated H2S concentration within the inflamed paw was visualized and quantified by both PET imaging and Cerenkov luminescence (Figure 14C,D). Moreover, the 64Cu‐cyclen could be also used to detect the defect site in the myocardium from an acute myocardial infarction (MI) model (Figure 14E–H). As such, this radioactive probe demonstrated great potential as a powerful nanoplatform providing efficient detection, accurate quantification, and nuclear imaging of H2S within living animals.

Figure 14.

Figure 14

A) Schematic of the formation of 64CuS via 64Cu–cyclen and H2S. B) The detection of H2S in vivo: a) Cerenkov luminescence images of the SD rats injected with Matrigel (top left), Matrigel + NaCl (top right), H2S gas dissolved in solution (bottom left) and NaHS (bottom right) respectively on the back at 0‐hour postinjection of 64Cu‐cyclen; b) The PET image of the injection site at 4 h postinjection (“L” stands for liver); c) The cerenkov luminescence images of SD rats injected with 64CuCl2 (top left), 64CuS (top right), 64Cu–cyclen (bottom left), and 64Cu–cyclam (bottom right) on the back at 0 h postinjection, and d) 4 h postinjection; e) The clearance of remained sample in a time pattern. C) The cerenkov luminescence images of BALB/c mice with paw inflammation (developed by complete Freund's adjuvant) at 1 h postinjection of various of probes; D) The PET (maximum intensity projection)‐CT images obtained from the BALB/c mice with paw inflammation at 1 h post‐administration of different probes. E) The transverse PET/CT images of the rats with acute myocardial infarction (MI) at 4 h postinjection of 64Cu—cyclen. F) The transverse PET/CT images of the rats with MI at 4 h postinjection of 18F‐FDG. G) The fused coregisterion image of 64Cu–cyclen and 18F‐FDG. H) The quantitative analysis of PET imaging of the MI models (n = 4). Reproduced with permission.130 Copyright 2016, Wiley.

5. SHTS‐Based Nanomedicine for Disease Therapy

Following disease diagnosis, an effective, timely, and in situ treatment is highly demanded. In comparison to imaging agents, smart nanoplatforms could combine imaging, diagnosis, and therapy simultaneously. As highly‐expressed H2S within the disease area as a trigger, multifunctional nanoagents can serve as imaging and therapeutic agents simultaneously. As mentioned previously, the H2S functions as an important biological indicator and also has vital roles in a series of physiological functions, such as factors for protecting or killing cells. However, the application of most H2S donors is restricted by the short half‐life and low hydrophilic property. Due to these limitations, several H2S‐releasing nanomaterials were developed for various disease therapies. In this following section, these latest nanoagents designed for tumor diagnosis and treatment enabled by endogenous H2S activation will be discussed (Table 4 ). Additionally, the exogenous H2S delivering nanoplatforms employed for tumor therapy, ischemic/reperfusion protection, and transplanted organ preservation will be summarized.

Table 4.

Multifunctional nanoplatforms for SHTS‐based imaging and therapy

Imaging strategy a) Material Nanoparticles Size [nm] Therapeutic mechanism Administration Disease Ref.
FL MOF Cu2(ZnTcpp)·H2O 120 Photodynamic Intratumoral Colorectal cancer 55
NIR Polymer Nano‐PT 8.4–15 Photothermal Subcutaneous Colorectal cancer 175
PA Cu Cu2O 21 Photothermal Intravenous Colorectal cancer 54
US/MRI Liposome AML ≈200 Bubble/H2S bomb Intravenous Hepatocellula cancer 56
N/A Silica DATS‐MSN ≈225 ± 35 GSH triggered‐release H2S Intravenous Heart I/R injury 176
DATS‐MSN ≈225 ± 35 GSH triggered‐release H2S Intravenous Myocardial I/R Injury 57
DATS‐MSN 175 ± 35 GSH triggered‐release H2S Preoperative treatment CAV 177
a)

I/R: Ischemic/reperfusion; US: Ultrasound; MRI: Magnetic resonance imaging; CAV: Cardiac allograft vasculopathy, MSN: Mesoporous silica nanoparticles.

5.1. Endogenous H2S‐Triggered Photodynamic Therapy

Under a specific wavelength (e.g., near‐infrared light), photosensitizing agents generate reactive oxygen species (ROS) for treatment of diseases such as bacterial infection or cancers, referred to as photodynamic therapy (PDT).178, 179, 180 Compared with conventional therapies such as chemotherapy and radiotherapy, PDT is an ideal strategy to treat cancer (i.e., lead the cellular apoptosis and necrosis via the ROS activated) since it is noninvasive, safe, and convenient.181 However, photosensitizing agents (e.g., porphyrin) typically cannot elicit an antitumor PDT effect due to their physiochemical features (e.g., hydrophobic) nor are able to diagnose cancer. As such, nanomaterial alternatives have arisen as an attempt to effectively implement this therapeutic strategy. As an example, Ma et al. developed a smart, H2S‐triggered MOF nanosensor acted as a photosensitizer after exposure to H2S (Figure 15 ).55 This novel MOF, (Cu2(ZnTcpp)·H2O)n (NP‐1) was synthesized using a reverse microemulsion system followed by a hydrothermal treatment. NP‐1 reacted quickly with H2S within one minute to recover red fluorescence (≈Em610 and Em660). A linear logarithmic relationship was found for the fluorescence intensity and NaHS concentration (from 10–70 × 10−6 m) (Figure 15A,B). As a potential photosensitizer, the NP‐1 showed better PDT efficacy than the ZnTCPP precursor (Figure 15C). Specifically, NP‐1 (10 × 10−6 m) responded only to laser irradiation (600 nm) to generate 1O2 when H2S (50 × 10−6 m) was present. In comparison, when not irradiated or H2S was absent, NP‐1 was unable to damage to HepG2 human liver cancer cells (Figure 15C). After intratumoral injection and irradiation, NP‐1 was detrimental to the HCT‐116 cells (high H2S levels) and nearly eradicated the entire tumor (Figure 15D–G). Tumor shrinkage was also observed for mice injected with ZnTcpp following irradiation, but the therapeutic effect was relatively poor compared with NP‐1. The role of H2S in irradiation‐induced damage was confirmed using HCT‐116 cells (Figure 15H). Although this intelligent nanoplatform, NP‐1 shows significant potential as a H2S‐selective photosensitizing agent for PDT of cancer, further functionalization using PEGylation to enable the whole body circulation is highly recommended.

Figure 15.

Figure 15

A) The change of fluorescence spectra of NP‐1 after incubating with HS (0 × 10−6 to 10 × 10−6 m). B) The linear relationship between the fluorescence intensity of MOF NP‐1 and the NaHS's concentration. C) Confocal images obtained from the HepG2 cells with calcein‐AM and PI staining after the following treatments: a) 10 × 10−3 m MOF NP‐1; b) 10 × 10−3 m MOF NP‐1 + 50 × 10−3 m NaHS; c) 10 × 10−3 m MOF NP‐1 + irradiation; d) 10 × 10−3 m MOF NP‐1 + 50 × 10−3 m + irradiation. D) Optical images of the nude mice bearing HCT‐116 tumor with different treatments (before treatment, upper raw; after treatment, down raw): a) PBS administration; b) PBS injection followed by irradiation; c) ZnTcpp administration followed by irradiation; d) Cu(ZnTcpp) (MOF NP‐1) injection; e) Cu(ZnTcpp) injection followed by irradiation. E) The growth inhibition curve of tumor among different treatment groups. F) The body weight of mice from different therapy. G) Optical images of tumors extracted from MOF NP‐1 (upper row) and control (down raw) groups after irradiation. H) The MTT assay of the HCT116 cells treated with various concentrations of MOF NP‐1 with or without irradiation. Reproduced with permission.55 Copyright 2016, Wiley.

5.2. Endogenous H2S‐Triggered Photothermal Therapy

As an additional photodynamic treatment, photothermal therapy (PTT) can damage or kill cancer cells by generating vibrational energy in the form of heat after electromagnetic radiation.37, 182, 183, 184, 185 Many nanomaterials, including gold nanorods and graphene, have been employed as PTT photosensitizers using NIR excitation.157, 186 Nevertheless, the scatted nanoagent would cause further damage to surrounding normal tissues after a laser applied. Therefore, targeting or selective ability is strongly required. Recently, an innovative nanoagent (Nano‐PT) was synthesized via self‐assembly of a H2S activated small molecule that is consist of a hydrophilic tail and a BODIPY core (Figure 16 A,B).175 As previously mentioned, the absorption wavelength of BODIPY changed after interaction with H2S. The variation (i.e., the change of wavelength from Ab540 to Ab790) enables the Nano‐PT to absorb NIR irradiation (785 nm laser, 5.37 W cm−2) and produce heat that can reach around 55° after 10 min of irradiation (Figure 16C). However, the temperature of the Nano‐PT solution only slightly increased when H2S was absent. After the introduction of H2S, a bright NIR‐II fluorescence signal (around Em950) was activated, and continuingly enhanced in a time‐dependent pattern, with a LOD value at 106 × 10−9 m (Figure 16D). With such effective sensitivity, the HCT‐116 tumor could be identified from normal tissue 2 h post the subcutaneous injection of Nano‐PT (Figure 16E). Importantly, a 20‐degree temperature difference between normal (41.8 °C) and tumor (60.9 °C) tissue could well prevent accidental injury of nearby tissue. Furthermore, PTT mediated by Nano‐PT successfully ablated the HCT‐116 tumor and limited any noticeable damage to the surrounding healthy tissue (Figure 16F,G).

Figure 16.

Figure 16

A) Schematic of Nano‐PT synthesis, the chemical structures of the components, and the transformation of SSS after the presence of H2S. B) Schematic illustration of the NIR‐II‐guided photothermal therapy for colorectal cancer mediated by Nano‐PT nanoplatform. C) The temperature curves of PBS, Nano‐PT, and Nano‐PT + NaHS (100 × 10−6 m) under laser irradiation. D) The change of NIR‐II fluorescence spectra of Nano‐PT during a series of time points (0–15 min) with NaHS (100 × 10−6 m), and the NIR‐II image of Nano‐PT after the H2S activation. E) The NIR‐II in vivo images of the normal and HCT‐116 tumor tissue on nude mice after on‐site subcutaneous injection of Nano‐PT at different time points. F) The ratios of tumor weight (W d15/W d0) among tumors collected from different groups (1) Control; 2) Nano‐PT; 3) Laser; 4) Nano‐PT + Laser) at day 15 and the corresponding photos of representative tumor tissues. G) The optical images of representative mice from different treated groups (1) Control; 2) Nano‐PT; 3) Laser; 4) Nano‐PT + Laser) at a series of time points; tumor sites has been indicated by red circles. Reproduced with permission.177 Copyright 2018, Wiley.

By intratumorally or subcutaneously administration, these nanoplatforms are able to treat noticeable tumors with PDT and PTT. However, these strategies are limited for clinical applications that often require simultaneous diagnosis and therapy. To achieve this, Yang's lab recently designed a H2S activated nanomaterial, Cu2O (21 nm), for colon cancer (HCT‐116, CBS overexpression) theranostics (Figure 17 A).54 After encountering endogenous H2S at the tumor site, Cu2O formed Cu9S8 which absorbed NIR irradiation (808 nm) and increased the tumor tissue temperature by 20.7 °C. Additionally, the formation of Cu9S8 provided a stable PA imaging agent that was unaffected by pH variations or GSH. For better efficiency, SAM (S‐adenosyl‐l‐methionine) or AOAA (amino‐oxyacetic acid) were administered by intravenous injection as a CBS activator and inhibitor, respectively. After supplementation of Cu2O with SAM, increased PA intensity was found at the tumor site (Figure 17B,C). While PA signal from Cu2O was detected, it failed to identify the tumor area due to its relatively lower intensity. Similarly, the CBS activator dramatically enhanced the temperature elevation with SAM + Cu2O treatment (15 °C), which was twice that of the Cu2O treated mice (Figure 17D,E). After two weeks of treatment with SAM + Cu2O and laser irradiation, HCT‐116 tumor‐bearing mice were completely eradicated (Figure 17F–H). In comparison, the size of the tumor treated with Cu2O + irradiation only slightly decreased. Thus, the reported Cu2O nanoparticle was an intelligent theranostic agent for clinic application after supplementation with SAM.

Figure 17.

Figure 17

A) The characterization of Cu2O and Cu9S8 nanoparticles: a) Schematic of the H2S‐induced transformation of Cu2O to Cu9S8; b) XRD patterns of the Cu2O and Cu9S8 nanoparticles; c,d) TEM images of the Cu2O and Cu9S8 nanoparticles; e,f) HR‐TEM images of the Cu2O and Cu9S8 nanoparticles; g,h) SAED patterns of the Cu2O and Cu9S8 nanoparticles. B) In vivo PA images of the mice bearing HCT‐116 tumor at various time points with different treatments. C) The corresponding PA intensities within the tumors. D) The in vivo thermal imaging of the mice carrying HCT‐116 tumor through a period of time after different treatments. E) The corresponding temperature change curve post 5 min irradiation. F) The optical images of representative mice bearing tumor from various therapeutic groups at day 16 posttreatment. G) The growth curve of tumor from different groups from 0 to 16 days. H) The representative tumor tissue harvested at day 16 postdifferent treatments. Reproduced with permission.54 Copyright 2018, Wiley.

5.3. Nanoplatforms as Exogenous H2S Delivery System

Low concentrations of H2S are widely known to aid the proliferation of cancer cells and surrounding vessels.4, 61 However, sufficient H2S quickly released in tumor tissue affects cellular metabolism and has a toxic effect on tumor cells.4 Exploiting this, Liu et al designed a H2S‐generating “nanobomber” for cancer therapy (Figure 18 A).56 This nanoliposomes (AML) was loaded with the H2S donors, anethole dithiolethione (ADT) and magnetic nanoparticles (MNPs), and had a diameter around 200 nm. The ADT could be activated enzymatically to continuingly release significant H2S gas, eventually forming microsized bubbles (Figure 18B). The H2S bubbles rapidly occupied most of the intracellular space and caused the apparent morphology changes,) which was strongly cytotoxic to HepG2 cells, with more than 40% death after 12 h (Figure 18C). These microbubbles were detected using ultrasonic imaging. After loading with MNPs, the AML accumulated in the tumor area under a magnetic field, which was around 3.4 times of that of Als (without MNPs) at 4 h postinjection (Figure 18D–F). Ultrasonic treatment was then applied was applied to burst the intratumoral microsized bubbles and subsequently induce physical damage and H2S‐induced cytotoxicity to the tumor tissue. The magnetic‐guided as therapy successfully induced cell apoptosis (with 21.5 ± 7.4%) and suppressed the tumor growth up to 7 days. However, treatment without the magnetic field showed relatively lower therapeutic effect and decreased apoptosis rates (15.4 ± 4.5%) (Figure 18G). In conclusion, this combined imaging system strongly enhanced the targeting accuracy during the treatment w will also providing the “H2S air bomber” for a novel cancer therapy strategy.

Figure 18.

Figure 18

A) Schematic of the combination tumor therapy mediated by the AMLs (anethole dithiolethione (ADT)‐loaded magnetic nanoliposome) nanoplatform. B) The optical images of the cellular morphology change and the bubble generated inside at 12 and 24 h after the incubation with AMLs (upper raw), ALs (middle raw), and liposomes (down raw) respectively; the generated bubbles and the serious membrane disruption have been indicated by red arrows. C) The HepG2 cell viability after the incubations with various samples for different time periods; the statistical difference is shown by **p < 0.01 and *p < 0.05. D) The in vivo ultrasonic and E) T2 MR imaging of the HepG2 tumor area at 12 and 24 h post the injections of AMLs (upper raw), ALs (middle raw), and liposomes (down raw). F) The DiR‐fluorescence images of a HepG2 bearing mice with the injection of DiR‐AMLs under external magnetic field (down raw) or no (upper raw) at 12 and 24 h. G) The TUNEL assay on tumor tissue obtained. Scale bars = 20 µm. Reproduced with permission.56 Copyright 2017, American Chemical Society.

Supplementation of H2S can help preserve organs and protect injuries triggered by ischemia/reperfusion by various antiapoptotic, antiinflammatory and antioxidative methods.187, 188, 189 However, most H2S donors cannot produce decent protection due to burst release and poor solubility, such as the NaHS or diallyl sulfide (DATS). Mesoporous silica nanoparticles (MSNs) have arisen as ideal nanoplatforms due to their large surface area that can be diversely functionalized, adjustable pore size for loading various cargo (e.g., the hydrophobic drug), and overall biocompatibility.190, 191 Recently, Wang's lab successfully developed DATS‐loaded MSNs as a H2S‐generating platform for protecting organs from I/R injury and transplantation.57, 176, 177 These MSN (175–225 nm) efficiently carried DATS at the surface pore (≈2 nm) because of the high affinity between DATS and Si‐OH, with an entrapment rate around 99% (Figure 19 A).176 A sustained DATS release profile (reaching about 80 min) was achieved after loaded on MSN and in the presence of GSH in the solution. In turn, the amount of H2S released from DATS alone quickly declined after only one hour. The supplementation of DATS‐MSN in the preserving solution effectively reduced inflammation in the transplanted organ by downregulating the expression level of intercellular adhesion molecule‐1 (ICAM‐1) and vascular cell adhesion molecule‐1 (VACM‐1).177 Notably, the DATS‐MSN continuingly released H2S into the plasma for up to 12 h, while NaHS and DATS quickly decreased after one or three hours respectively (Figure 19B).57 The administration of DATS‐MSN reduced myocardial apoptosis by approximately 15% at 24 h post‐reperfusion. Additionally, DATS‐MSN and substantially decreased I/R injury in myocardial tissues, which was confirmed using TTC staining (percentage of infarction area (INF)/area at risk (AAR)) (Figure 19C,D). More importantly, the DATS‐MSN exhibited superior protection of the heart after I/R injury in comparison to GYY4137, a conventional H2S donor with slow release kinetics (Figure 19E,F).

Figure 19.

Figure 19

A) Schematic of a GSH‐mediated DATS‐MSN nanoplatform for sustained release of H2S. B) The curve of H2S concentrations in the mice plasma from different groups overtimes. C) The apoptosis rate of cardiomyocytes after the myocardial ischemia/reperfusion (I/R) injury, which is shown by positive cell percentage in the TUNEL staining. D) The representative photographs of mid‐myocardial cross sections with TTC staining at 72 h post I/R injury. E) The concentration of H2S within the plasma from GYY4137 or DATS‐MSN treated groups during the 12 h after I/R injury. F) H2S concentrations in the plasma and myocardium from GYY4137 or DATS‐MSN treated mice at 72 h after I/R injury. Reproduced with permission.57 Copyright 2017, Nature Research.

6. Conclusion and Future Outlook

Undoubtedly, early diagnosis significantly contributes to attaining successful therapeutic interventions.192 Early diagnosis—especially for cancer—is likely to increase the efficacy of nearly every therapy, ranging from surgery, chemotherapy, radiotherapy to immunotherapy. In addition screening specific diseases' biomarkers (e.g., tumor surface markers), proper surveillance of the influential gasotransmitters would effectively aid disease diagnosis at early stages.193 Of these, H2S is vitally important in a series of signaling pathways associated with various physiological (e.g., antiinflammation and antiapoptosis) and pathological effects (e.g., tumor progress, etc.).194 Additionally, the high toxicity of H2S further emphasizes the importance of monitoring H2S, especially for potential air exposures. Currently, several organic probes have been implemented for detecting/imaging H2S. However, widespread applicability is restricted by their poor physiochemical conditions, including relatively weak sensitivity and limited circulation.13, 14

Advanced nanomaterials have demonstrated desirable properties as multifunctional platforms for imaging and therapy.49, 195 In recent years, nanomaterials have been continually developed as novel probes for H2S‐triggered detection, imaging, and therapy (Figure 1). This review summarizes and discusses all SHTS‐based nanomedicines to date, focusing on H2S imaging of cancer cells and in tumor‐bearing mice as well as for disease therapy (e.g., cancer or I/R injury) (Table 5 ). More specifically, various H2S imaging approaches using fluorescence, LSPR, UCL, NIR, PA, and PET modalities are summarized. Therapeutic strategies, such as photodynamic and photothermal therapy, influenced by the presences of H2S are also discussed in detail. To provide more ideas for the H2S related treatments, the H2S generated nanoplatforms have been included as well. Undeniably, the development of SHTS‐based nanomedicine has seen much progress accelerated by the efforts of researchers. However, there are still several principles and challenges that need to be addressed in future H2S‐nanoprobe designs. Below we provide a series of considerations regarding these crucial issues for future SHTS‐base nanomedicine innovation and translation (Figure 20 ).

Table 5.

The nanoagents involved in SHTS

Material a) In vitro detection/imaging In vivo imaging Therapy Number of Application Features
CM EC FL Others H2S‐triggered H2S delivery In Vitro In Vivo Cons Pros
NMNCs/NPs ✓✓ DFI 19 0

Limited imaging depth;

In vitro detection only;

Expensive

High sensitivity;

Direct reaction with H2S;

Eye‐visible detection;

Reusability

C‐dot 7 0

Limited imaging depth;

In vitro detection only

High biocompatibility;

Affordable and reproducible preparation

Cu ✓✓ PET PT 7 2 Low biocompatibility

Quick and direct reaction with H2S;

Gas detection

Silica NIR/PA 1 5

Relatively high cytotoxicity;

Limited circulation

Easy functionalization;

Strong capability in drug loading

LNPs/PMNs NIR/US/MRI PT/BB 0 3 Relatively low stability Desirable biocompatibility and circulation
MOF FL PD 8 1

Limited circulation;

Relatively large size;

Poor in vivo imaging (FL)

Large surface area for modification;

Direct reaction with H2S via the cation carried

UCNPs UCL UCL 2 3 Relatively high cytotoxicity

Desirable imaging penetration;

Consistent imaging reference for calibration

a)

NMNCs/NPs: Noble metal nanoclusters/nanoparticles; CM: Colorimetry; EC: Electrochemistry; FL: Fluorescence; DFI: Dark field imaging; UCL: Upconversion luminescence; NIR: Near infrared; PA: photoacoustic imaging; PET: positron emission tomography; PD: Photodynamic; PT: Photothermal; BB: Bubble bomb.

Figure 20.

Figure 20

The current status and barriers that need to be overcome for future development of smart H2S‐triggered/therapeutic system (SHTS).

6.1. Challenge

Due to physiochemical properties, H2S quickly dissolves in water and results in the formation of HS and S2− that introduce interference. Additionally, toxic H2S generated from cells is processed rapidly by anabolism and catabolism. Due to this dynamic nature, real‐time imaging of H2S is highly demanded to inform the location/status of disease (e.g., cancer) following therapy. In summary, a specific, sensitive, and multifunctional H2S sensor with excellent circulation (for reaching the specific area) is ideal for H2S detection and therapy.

6.2. Influence of Size, Shape, and Charge

The morphology of nanomaterials, especially size, directly affects the optical features (e.g., LSPR) and contacting area. Both of these aspects are strongly related to the sensitivity toward H2S. Additionally, large nanoparticle (>200 nm) tend to absorb more serum proteins (34% absorbance) compared with smaller ones (80 nm, with 6% absorbance). This results in only smaller nanoparticles having a circulation half‐life suitable for imaging.196 Additionally, the nanomaterials biodistribution is significantly affected by their shape and surface charge.197, 198, 199 For instance, tumor tissue accumulation is enhanced with negatively charged NPs.198, 199 Thus, varying the diameter, shape, and charge alter biodistribution and tumor penetration and subsequently influence the efficiency of imaging and therapy.200, 201

6.3. Surface Modification

Although the H2S detection (e.g., solution, serum or H2S in the air) can be performed with unmodified nanomaterials, surface modifications (e.g., PEGlaytion, acetylation, amino acid or ligand/antibody functionalization) greatly increase their stability, biocompatibility, circulation and targeting for in vivo sensing/delivery.202, 203 Other surface modifications of functional groups or material (e.g., Cyclam‐Cu2+ or FRET acceptor)45, 122 can impart an alternative strategy that affords a specific nanomaterial (such as Au nanorod with photothermal strategy) with H2S‐selectivity.

6.4. Accuracy of Real‐Time H2S Concentration

During in vivo imaging, interfering background signal from tissue autofluorescence (e.g., skin) greatly affects H2S visualization. Although most in vivo NIR or PET imaging agents limit the autofluorescence background, the accuracy of H2S detection or imaging would be further influenced by the variation among individuals. As an ideal imaging system, UCNPs can greatly reduce autofluorescence. Additionally, the unique ratiometric strategy applied (i.e., the ratio of specific emission/a control emission) ensure sensing accuracy. Thus, we believe the incorporation of a reference emission using surface modification or reagent loading will increase imaging accuracy during diagnosis and therapy.

6.5. Sensitivity Enhancement for In Vivo Imaging

As mentioned above, the biological half‐life of H2S is short. Typically, biological concentrations are generally lower than the LOD of most nanoagents. To improve the detection performance, an enhancement (e.g, SAM) agent is strongly recommended, especially for H2S‐triggered therapeutic nanoplatforms.54

6.6. Therapeutic Strategy

A series of combined therapies including photodynamic, photothermal, and gas‐generated treatments, have been listed in this review. These smart nanoplatforms are all H2S‐regulated and mitigate damage to surrounding tissue. However, the potential problems, including the releasing speed and the concentration of H2S generated within a certain area, must be controlled. Meanwhile, additional agents, such as chemical drugs or vaccine adjuvants (e.g., CpG ODN) could be further loaded for combined chemotherapy or immunotherapy after H2S activation.

6.7. Applications and Selection of Nanosensor

Given diverse applications for SHTS‐based nanomedicine, proper nanoplatform selection is critical. For the detection of H2S in solution, biosample, and air, the priority of nanosensor selection is the selective, sensitivity, and practicality. For instance, the sensors with a physical supporting (e.g., supporting membrane) or an eye‐visible colorimetric examination would be more practical and convenient. Alternatively, biocompatibility and circulation half‐life are the key factors for in vivo imaging and therapy. Although great progress has been made in the development of nanomaterials as H2S sensors with high sensitivity and selectivity, only a few can apply in the in vivo assay due to the bad biocompatibility and circulation. Thus, to promote the real application of SHTS based nanomedicine and its following clinic translation, more efforts should be dedicated to investigating these aspects.

In a sharp comparison of general strategies, the advances of nanotechnology enable us to combine various functions into one nanoagent. With SHTS‐based nanomedicine, we are able to detect and imaging H2S for different applications, and also induce specific therapy following the diagnosis. The increasing interest in real‐time H2S imaging and high performance of SHTS would encourage the further investigation of the following translation in the clinic, which will greatly improve the diagnosis of various H2S diagnosis and benefit the patients via a safe and efficient therapeutic strategy.

Conflict of Interest

The authors declare no conflict of interest.

Acknowledgements

The authors acknowledge the financial support from the University of Wisconsin‐Madison and the National Institutes of Health (P30CA014520).

Biographies

Weiyu Chen received his Ph.D. in 2018 from the University of Queensland, Australia under the supervision of Prof. Zhiping Xu. Subsequently, he joined the Department of Radiology, University of Wisconsin‐Madison, as a postdoctoral fellow under the supervision of Prof. Weibo Cai. His research interests focus on the design, synthesis, and biomedical applications of nanoplatforms.

graphic file with name ADVS-6-1901724-g022.gif

Dalong Ni received his Ph.D. degree in 2016 from the Shanghai Institute of Ceramics, Chinese Academy of Sciences. He then joined the Department of Radiology at UW‐Madison as a postdoctoral fellow under the supervision of Prof. Weibo Cai, working on the design and synthesis of multifunctional nanoplatforms for biomedical applications.

graphic file with name ADVS-6-1901724-g023.gif

Weibo Cai received his Ph.D. degree from the University of California at San Diego in 2004 and is now a professor at UW‐Madison (http://mi.wisc.edu). His research is primarily focused on molecular imaging and nanotechnology, investigating the biomedical applications of various agents developed in his laboratory for imaging and therapy of various diseases.

graphic file with name ADVS-6-1901724-g024.gif

Chen W., Ni D., Rosenkrans Z. T., Cao T., Cai W., Smart H2S‐Triggered/Therapeutic System (SHTS)‐Based Nanomedicine. Adv. Sci. 2019, 6, 1901724 10.1002/advs.201901724

Contributor Information

Dalong Ni, Email: dni2@wisc.edu.

Weibo Cai, Email: wcai@uwhealth.org.

References

  • 1. Malone Rubright S. L., Pearce L. L., Peterson J., Nitric Oxide 2017, 71, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Policastro M. A., Otten E. J., J. Med. Toxicol. 2007, 3, 73. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3. Reiffenstein R. J., Hulbert W. C., Roth S. H., Annu. Rev. Pharmacol. Toxicol. 1992, 32, 109. [DOI] [PubMed] [Google Scholar]
  • 4. Szabo C., Nat. Rev. Drug Discovery 2016, 15, 185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5. Wang R., Trends Biochem. Sci. 2014, 39, 227. [DOI] [PubMed] [Google Scholar]
  • 6. Paul B. D., Snyder S. H., Trends Biochem. Sci. 2015, 40, 687. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Wallace J. L., Wang R., Nat. Rev. Drug Discovery 2015, 14, 329. [DOI] [PubMed] [Google Scholar]
  • 8. Wang R., Physiol. Rev. 2012, 92, 791. [DOI] [PubMed] [Google Scholar]
  • 9. Guo Z., Chen G. Q., Zeng G. M., Li Z. W., Chen A. W., Wang J. J., Jiang L. B., Analyst 2015, 140, 1772. [DOI] [PubMed] [Google Scholar]
  • 10. Lippert A. R., New E. J., Chang C. J., J. Am. Chem. Soc. 2011, 133, 10078. [DOI] [PubMed] [Google Scholar]
  • 11. Sasakura K., Hanaoka K., Shibuya N., Mikami Y., Kimura Y., Komatsu T., Ueno T., Terai T., Kimura H., Naganot T., J. Am. Chem. Soc. 2011, 133, 18003. [DOI] [PubMed] [Google Scholar]
  • 12. Liu C. R., Pan J., Li S., Zhao Y., Wu L. Y., Berkman C. E., Whorton A. R., Xian M., Angew. Chem., Int. Ed. 2011, 50, 10327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Zhang K., Zhang J., Xi Z., Li L. Y., Gu X. X., Zhang Q. Z., Yi L., Chem. Sci. 2017, 8, 2776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14. Cao J., Lopez R., Thacker J. M., Moon J. Y., Jiang C., Morris S. N. S., Bauer J. H., Tao P., Mason R. P., Lippert A. R., Chem. Sci. 2015, 6, 1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15. Wang Y., Sun S., Zhang Z., Shi D., Adv. Mater. 2018, 30, e1705660. [DOI] [PubMed] [Google Scholar]
  • 16. Chen H., Gu Z., An H., Chen C., Chen J., Cui R., Chen S., Chen W., Chen X., Chen X., Chen Z., Ding B., Dong Q., Fan Q., Fu T., Hou D., Jiang Q., Ke H., Jiang X., Liu G., Li S., Li T., Liu Z., Nie G., Ovais M., Pang D., Qiu N., Shen Y., Tian H., Wang C., Wang H., Wang Z., Xu H., Xu J.‐F., Yang X., Zhu S., Zheng X., Zhang X., Zhao Y., Tan W., Zhang X., Zhao Y., Sci. China: Chem. 2018, 61, 1503. [Google Scholar]
  • 17. Smith B. R., Gambhir S. S., Chem. Rev. 2017, 117, 901. [DOI] [PubMed] [Google Scholar]
  • 18. Lu Y., Aimetti A. A., Langer R., Gu Z., Nat. Rev. Mater. 2016, 2, 16075. [Google Scholar]
  • 19. Sun T., Zhang Y. S., Pang B., Hyun D. C., Yang M., Xia Y., Angew. Chem., Int. Ed. 2014, 53, 12320. [DOI] [PubMed] [Google Scholar]
  • 20. Kim D., Shin K., Kwon S. G., Hyeon T., Adv. Mater. 2018, 30, e1802309. [DOI] [PubMed] [Google Scholar]
  • 21. Wu J., Wang X., Wang Q., Lou Z., Li S., Zhu Y., Qin L., Wei H., Chem. Soc. Rev. 2018, 42, 6060. [Google Scholar]
  • 22. Sun S. K., Wang H. F., Yan X. P., Acc. Chem. Res. 2018, 51, 1131. [DOI] [PubMed] [Google Scholar]
  • 23. Chen W. Y., Zhang B., Mahony T., Gu W. Y., Rolfe B., Xu Z. P., Small 2016, 12, 1627. [DOI] [PubMed] [Google Scholar]
  • 24. Li B., Tang J., Chen W. Y., Hao G. Y., Kurniawan N., Gu Z., Xu Z. P., Biomaterials 2018, 177, 40. [DOI] [PubMed] [Google Scholar]
  • 25. Davis M. E., Chen Z. G., Shin D. M., Nat. Rev. Drug Discovery 2008, 7, 771. [DOI] [PubMed] [Google Scholar]
  • 26. Ni D., Jiang D., Im H. J., Valdovinos H. F., Yu B., Goel S., Barnhart T. E., Huang P., Cai W., Biomaterials 2018, 171, 144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Yang B., Chen Y., Shi J., Chem. Rev. 2019, 119, 84881. [DOI] [PubMed] [Google Scholar]
  • 28. Song G., Cheng L., Chao Y., Yang K., Liu Z., Adv. Mater. 2017, 29, 1700996. [DOI] [PubMed] [Google Scholar]
  • 29. Jiang Y., Pu K., Acc. Chem. Res. 2018, 51, 1840. [DOI] [PubMed] [Google Scholar]
  • 30. Xie J., Gong L., Zhu S., Yong Y., Gu Z., Zhao Y., Adv. Mater. 2018, 31, e1802244. [DOI] [PubMed] [Google Scholar]
  • 31. Liu Y., Jiang Y., Zhang M., Tang Z., He M., Bu W., Acc. Chem. Res. 2018, 51, 2502. [DOI] [PubMed] [Google Scholar]
  • 32. Chen W., Zuo H., Rolfe B., Schembri M. A., Cobbold R. N., Zhang B., Mahony T. J., Xu Z. P., J. Controlled Release 2018, 292, 196. [DOI] [PubMed] [Google Scholar]
  • 33. Chen W., Zuo H., Zhang E., Li L., Henrich‐Noack P., Cooper H., Qian Y., Xu Z. P., ACS Appl. Mater. Interfaces 2018, 10, 20326. [DOI] [PubMed] [Google Scholar]
  • 34. Peng J. J., Teoh C. L., Zeng X., Samanta A., Wang L., Xu W., Su D. D., Yuan L., Liu X. G., Chang Y. T., Adv. Funct. Mater. 2016, 26, 191. [Google Scholar]
  • 35. Song S. P., Qin Y., He Y., Huang Q., Fan C. H., Chen H. Y., Chem. Soc. Rev. 2010, 39, 4234. [DOI] [PubMed] [Google Scholar]
  • 36. Rosi N. L., Mirkin C. A., Chem. Rev. 2005, 105, 1547. [DOI] [PubMed] [Google Scholar]
  • 37. Ni D., Jiang D., Valdovinos H. F., Ehlerding E. B., Yu B., Barnhart T. E., Huang P., Cai W., Nano. Lett. 2017, 17, 3282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Shi B., Gu X. F., Fei Q., Zhao C. C., Chem. Sci. 2017, 8, 2150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Zhang X., Zhang Q., Yue D., Zhang J., Wang J. T., Li B., Yang Y., Cui Y. J., Qian G. D., Small 2018, 14, 7. [DOI] [PubMed] [Google Scholar]
  • 40. Zhang L. N., Wang Z. W., Zhang J. B., Jia J. B., Zhao D., Fan Y. C., Nanomaterials 2018, 8, 11. [Google Scholar]
  • 41. Xiong B., Zhou R., Hao J. R., Jia Y. H., He Y., Yeung E. S., Nat. Commun. 2013, 4, 9. [DOI] [PubMed] [Google Scholar]
  • 42. Shanmugaraj K., Ilanchelian M., Microchim. Acta 2016, 183, 1721. [Google Scholar]
  • 43. Zhang Y., Shen H. Y., Hai X., Chen X. W., Wang J. H., Anal. Chem. 2017, 89, 1346. [DOI] [PubMed] [Google Scholar]
  • 44. Zhao Y., Luo Y. D., Zhu Y. Y., Sun Y. L., Cui L. Y., Song Q. J., ACS Sustainable Chem. Eng. 2017, 5, 7912. [Google Scholar]
  • 45. Ma Y., Zhang C. Y., Yang P., Li X. Y., Tong L. L., Huang F., Yue J. Y., Tang B., Nanoscale 2018, 10, 15793. [DOI] [PubMed] [Google Scholar]
  • 46. Zhang X., Hu Q., Xia T. F., Zhang J., Yang Y., Cui Y. J., Chen B. L., Qian G. D., ACS Appl. Mater. Interfaces 2016, 8, 32259. [DOI] [PubMed] [Google Scholar]
  • 47. Dong Y. L., Wang L., Wang F., Li N., Jin Y., Zhang J. C., Yang X. J., Analyst 2017, 142, 4703. [DOI] [PubMed] [Google Scholar]
  • 48. Li X., Zhao H., Ji Y., Yin C., Li J., Yang Z., Tang Y. F., Zhang Q. C., Fan Q. L., Huang W., ACS Appl. Mater. Interfaces 2018, 10, 39544. [DOI] [PubMed] [Google Scholar]
  • 49. Zhao C. C., Zhang X. L., Li K. B., Zhu S. J., Guo Z. Q., Zhang L. L., Wang F. Y., Fei Q., Luo S. H., Shi P., Tian H., Zhu W. H., J. Am. Chem. Soc. 2015, 137, 8490. [DOI] [PubMed] [Google Scholar]
  • 50. Yu C. M., Li X. Z., Zeng F., Zheng F. Y., Wu S. Z., Chem. Commun. 2013, 49, 403. [DOI] [PubMed] [Google Scholar]
  • 51. Wang Z. X., Zheng C. L., Li Q. L., Ding S. N., Analyst 2014, 139, 1751. [DOI] [PubMed] [Google Scholar]
  • 52. Zhou L. S., Shen F. P., Tian X. K., Wang D. H., Zhang T., Chen W., Nanoscale 2013, 5, 1564. [DOI] [PubMed] [Google Scholar]
  • 53. Annanouch F. E., Haddi Z., Vallejos S., Umek P., Guttmann P., Bittencourt C., Llobet E., ACS Appl. Mater. Interfaces 2015, 7, 6842. [DOI] [PubMed] [Google Scholar]
  • 54. An L., Wang X. D., Rui X. C., Lin J. M., Yang H., Tian Q. W., Tao C., Yang S. P., Angew. Chem. Int. Ed. 2018, 57, 15782. [DOI] [PubMed] [Google Scholar]
  • 55. Ma Y., Li X. Y., Li A. J., Yang P., Zhang C. Y., Tang B., Angew. Chem. Int. Ed. 2017, 56, 13752. [DOI] [PubMed] [Google Scholar]
  • 56. Liu Y., Yang F., Yuan C. X., Li M. X., Wang T. T., Chen B., Jin J., Zhao P., Tong J. Y., Luo S. H., Gu N., ACS Nano 2017, 11, 1509. [DOI] [PubMed] [Google Scholar]
  • 57. Sun X. T., Wang W. S., Dai J., Jin S., Huang J. C., Guo C. F., Wang C. S., Pang L. W., Wang Y. Q., Sci. Rep. 2017, 7, 13.28144038 [Google Scholar]
  • 58. Paul B. D., Snyder S. H., Nat. Rev. Mol. Cell Biol. 2012, 13, 499. [DOI] [PubMed] [Google Scholar]
  • 59. Szabo C., Ransy C., Modis K., Andriamihaja M., Murghes B., Coletta C., Olah G., Yanagi K., Bouillaud F., Br. J. Pharmacol. 2014, 171, 2099. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60. Shibuya N., Tanaka M., Yoshida M., Ogasawara Y., Togawa T., Ishii K., Kimura H., Antioxid. Redox Signaling 2009, 11, 703. [DOI] [PubMed] [Google Scholar]
  • 61. Szabo C., Coletta C., Chao C., Modis K., Szczesny B., Papapetropoulos A., Hellmich M. R., Proc. Natl. Acad. Sci. USA 2013, 110, 12474. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Li L., Rose P., Moore P. K., Annu. Rev. Pharmacol. Toxicol. 2011, 51, 169. [DOI] [PubMed] [Google Scholar]
  • 63. Hu L. F., Lu M., Tiong C. X., Dawe G. S., Hu G., Bian J. S., Aging Cell 2010, 9, 135. [DOI] [PubMed] [Google Scholar]
  • 64. Fernandes V. S., Ribeiro A. S., Barahona M. V., Orensanz L. M., Martinez‐Saenz A., Recio P., Martinez A. C., Bustamante S., Carballido J., Garcia‐Sacristan A., Prieto D., Hernandez M., J. Urol. 2013, 190, 746. [DOI] [PubMed] [Google Scholar]
  • 65. Fiorucci S., Antonelli E., Distrutti E., Rizzo G., Mencarelli A., Orlandi S., Zanardo R., Renga B., Di Sante M., Morelli A., Cirino G., Wallace J. L., Gastroenterology 2005, 129, 1210. [DOI] [PubMed] [Google Scholar]
  • 66. Modis K., Coletta C., Erdelyi K., Papapetropoulos A., Szabo C., FASEB J. 2013, 27, 601. [DOI] [PubMed] [Google Scholar]
  • 67. Elrod J. W., Calvert J. W., Morrison J., Doeller J. E., Kraus D. W., Tao L., Jiao X. Y., Scalia R., Kiss L., Szabo C., Kimura H., Chow C. W., Lefer D. J., Proc. Natl. Acad. Sci. USA 2007, 104, 15560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 68. Calvert J. W., Jha S., Gundewar S., Elrod J. W., Ramachandran A., Pattillo C. B., Kevil C. G., Lefer D. J., Circ. Res. 2009, 105, 365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69. Wallace J. L., Wang R., Nat. Rev. Drug Discovery 2015, 14, 329. [DOI] [PubMed] [Google Scholar]
  • 70. Szabo C., Hellmich M. R., Cell Cycle 2013, 12, 2915. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 71. Cao X., Ding L., Xie Z. Z., Yang Y., Whiteman M., Moore P. K., Bian J. S., Antioxid. Redox Signaling 2019, 31, 1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72. Yamagishi K., Onuma K., Chiba Y., Yagi S., Aoki S., Sato T., Sugawara Y., Hosoya N., Saeki Y., Takahashi M., Fuji M., Ohsaka T., Okajima T., Akita K., Suzuki T., Senawongse P., Urushiyama A., Kawai K., Shoun H., Ishii Y., Ishikawa H., Sugiyama S., Nakajima M., Tsuboi M., Yamanaka T., Gut 2012, 61, 554. [DOI] [PubMed] [Google Scholar]
  • 73. Hellmich M. R., Coletta C., Chao C., Szabo C., Antioxid. Redox Signaling 2015, 22, 424. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74. Vitvitsky V., Kabil O., Banerjee R., Antioxid. Redox Signaling 2012, 17, 22. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 75. Hartle M. D., Pluth M. D., Chem. Soc. Rev. 2016, 45, 6108. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 76. Liu J. M., Wang X. X., Li F. M., Lin L. P., Cai W. L., Lin X., Zhang L. H., Li Z. M., Lin S. Q., Anal. Chim. Acta 2011, 708, 130. [DOI] [PubMed] [Google Scholar]
  • 77. Zhang J., Xu X. W., Yang X. R., Analyst 2012, 137, 1556. [DOI] [PubMed] [Google Scholar]
  • 78. Yang Y., Lei Y. J., Zhang X. R., Zhang S. C., Talanta 2016, 154, 190. [DOI] [PubMed] [Google Scholar]
  • 79. Yuan Z. Q., Peng M. H., Shi L., Du Y., Cai N., He Y., Chang H. T., Yeung E. S., Nanoscale 2013, 5, 4683. [DOI] [PubMed] [Google Scholar]
  • 80. Zhang J., Xu X. W., Yuan Y., Yang C., Yang X. R., ACS Appl. Mater. Interfaces 2011, 3, 2928. [DOI] [PubMed] [Google Scholar]
  • 81. Chen C. X., Zhao D., Lu L. X., Yang F., Yang X. R., Sens. Actuators, B 2015, 220, 1247. [Google Scholar]
  • 82. Zhang X., Zhou W. J., Yuan Z. Q., Lu C., Analyst 2015, 140, 7443. [DOI] [PubMed] [Google Scholar]
  • 83. Deng H. H., Weng S. H., Huang S. L., Zhang L. N., Liu A. L., Lin X. H., Chen W., Anal. Chim. Acta 2014, 852, 218. [DOI] [PubMed] [Google Scholar]
  • 84. Zhang Z. Y., Chen Z. P., Wang S. S., Qu C. L., Chen L. X., ACS Appl. Mater. Interfaces 2014, 6, 63007. [DOI] [PubMed] [Google Scholar]
  • 85. Gao Z. Q., Tang D. Y., Tang D. P., Niessner R., Knopp D., Anal. Chem. 2015, 87, 10153. [DOI] [PubMed] [Google Scholar]
  • 86. Wang Z. X., Zheng C. L., Ding S. N., RSC Adv. 2014, 4, 9825. [Google Scholar]
  • 87. Chen W. Y., Lan G. Y., Chang H. T., Anal. Chem. 2011, 83, 9450. [DOI] [PubMed] [Google Scholar]
  • 88. Mahapatra N., Datta S., Halder M., J. Photochem. Photobiol., A 2014, 275, 72. [DOI] [PubMed] [Google Scholar]
  • 89. Zheng X. B., Fan R. Q., Song Y., Wang A. N., Xing K., Du X., Wang P., Yang Y. L., J. Mater. Chem. C 2017, 5, 9943. [Google Scholar]
  • 90. Zheng X. B., Fan R. Q., Song Y., Xing K., Wang P., Yang Y. L., ACS Appl. Mater. Interfaces 2018, 10, 32698. [DOI] [PubMed] [Google Scholar]
  • 91. Guo L., Wang M., Cao D. P., Small 2018, 14, 6. [Google Scholar]
  • 92. Asad M., Sheikhi M. H., Pourfath M., Moradi M., Sens. Actuators, B 2015, 210, 1. [Google Scholar]
  • 93. Shao F., Hoffmann M. W. G., Prades J. D., Zamani R., Arbiol J., Morante J. R., Varechkina E., Rumyantseva M., Gaskov A., Giebelhaus I., Fischer T., Mathur S., Hernandez‐Ramirez F., Sens. Actuators, B 2013, 181, 130. [Google Scholar]
  • 94. Cui G. L., Zhang M. Z., Zou G. T., Sci. Rep. 2013, 3, 8. [Google Scholar]
  • 95. Chen P. C., Li Y. C., Ma J. Y., Huang J. Y., Chen C. F., Chang H. T., Sci. Rep. 2016, 6, 9.28442706 [Google Scholar]
  • 96. Li Z. H., Guo S., Lu C., Analyst 2015, 140, 2719. [DOI] [PubMed] [Google Scholar]
  • 97. Barati A., Shamsipur M., Abdollahi H., Sens. Actuators, B 2016, 230, 289. [Google Scholar]
  • 98. Singh S., Mitra K., Shukla A., Singh R., Gundampati R. K., Misra N., Maiti P., Ray B., Anal. Chem. 2017, 89, 783. [DOI] [PubMed] [Google Scholar]
  • 99. Su P. G., Peng Y. T., Sens. Actuators, B 2014, 193, 637. [Google Scholar]
  • 100. Song Z. L., Wei Z. R., Wang B., Luo Z., Xu S. M., Zhang W. K., Yu H. X., Li M., Huang Z., Zang J. F., Yi F., Liu H., Chem. Mater. 2016, 28, 1205. [Google Scholar]
  • 101. Chen J., Li Y., Zhong W. B., Hou Q. Y., Wang H., Sun X., Yi P. G., Sens. Actuators, B 2015, 206, 230. [Google Scholar]
  • 102. Wang Y., Hu J., Zhuang Q. F., Ni Y. N., ACS Sustainable Chem. Eng. 2016, 4, 2535. [Google Scholar]
  • 103. Zhou T., Wang N., Li C. H., Yuan H. Y., Xiao D., Anal. Chem. 2010, 82, 1705. [DOI] [PubMed] [Google Scholar]
  • 104. Willets K. A., Van Duyne R. P., Annu. Rev. Phys. Chem. 2007, 58, 267. [DOI] [PubMed] [Google Scholar]
  • 105. Park J., Jiang Q., Feng D., Mao L., Zhou H. C., J. Am. Chem. Soc. 2016, 138, 3518. [DOI] [PubMed] [Google Scholar]
  • 106. Pan X., Bai L., Wang H., Wu Q., Liu S., Xu B., Shi X., Liu H., Adv. Mater. 2018, 30, e1800180. [DOI] [PubMed] [Google Scholar]
  • 107. Chen D., Yang D., Dougherty C. A., Lu W., Wu H., He X., Cai T., Van Dort M. E., Ross B. D., Hong H., ACS Nano 2017, 11, 4315. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 108. Li J. R., Kuppler R. J., Zhou H. C., Chem. Soc. Rev. 2009, 38, 1477. [DOI] [PubMed] [Google Scholar]
  • 109. Yang Q., Xu Q., Jiang H. L., Chem. Soc. Rev. 2017, 46, 4774. [DOI] [PubMed] [Google Scholar]
  • 110. Furukawa H., Cordova K. E., O'Keeffe M., Yaghi O. M., Science 2013, 341, 1230444. [DOI] [PubMed] [Google Scholar]
  • 111. Cui Y. J., Li B., He H. J., Zhou W., Chen B. L., Qian G. D., Acc. Chem. Res. 2016, 49, 483. [DOI] [PubMed] [Google Scholar]
  • 112. Kreno L. E., Leong K., Farha O. K., Allendorf M., Van Duyne R. P., Hupp J. T., Chem. Rev. 2012, 112, 1105. [DOI] [PubMed] [Google Scholar]
  • 113. Gao X. H., Cui Y. Y., Levenson R. M., Chung L. W. K., Nie S. M., Nat. Biotechnol. 2004, 22, 969. [DOI] [PubMed] [Google Scholar]
  • 114. Baker S. N., Baker G. A., Angew. Chem., Int. Ed. Engl. 2010, 49, 6726. [DOI] [PubMed] [Google Scholar]
  • 115. Cao L., Wang X., Meziani M. J., Lu F., Wang H., Luo P. G., Lin Y., Harruff B. A., Veca L. M., Murray D., Xie S. Y., Sun Y. P., J. Am. Chem. Soc. 2007, 129, 11318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 116. Zhu A. W., Luo Z. Q., Ding C. Q., Li B., Zhou S., Wang R., Tian Y., Analyst 2014, 139, 1945. [DOI] [PubMed] [Google Scholar]
  • 117. Hou X. F., Zeng F., Du F. K., Wu S. Z., Nanotechnology 2013, 24, 9. [Google Scholar]
  • 118. Helmchen F., Denk W., Nat. Methods 2005, 2, 932. [DOI] [PubMed] [Google Scholar]
  • 119. Nimmerjahn A., Kirchhoff F., Helmchen F., Science 2005, 308, 1314. [DOI] [PubMed] [Google Scholar]
  • 120. Li Y. P., Zhang X., Zhang L., Jiang K., Cui Y. J., Yang Y., Qian G. D., J. Solid State Chem. 2017, 255, 97. [Google Scholar]
  • 121. Nandi S., Reinsch H., Banesh S., Stock N., Trivedi V., Biswas S., Dalton Trans. 2017, 46, 12856. [DOI] [PubMed] [Google Scholar]
  • 122. Chen J., Li Y., Lv K., Zhong W. B., Wang H., Wu Z., Yi P. G., Jiang J. H., Sens. Actuators, B 2016, 224, 298. [Google Scholar]
  • 123. Wang F. F., Zhang C. L., Qu X. T., Cheng S. S., Xian Y. Z., Biosens. Bioelectron. 2019, 126, 96. [DOI] [PubMed] [Google Scholar]
  • 124. Liu S. J., Zhang L. L., Yang T. S., Yang H. R., Zhang K. Y., Zhao X., Lv W., Yu Q., Zhang X. L., Zhao Q., Liu X. M., Huang W., ACS Appl. Mater. Interfaces 2014, 6, 11013. [DOI] [PubMed] [Google Scholar]
  • 125. Zhou Y., Chen W. Q., Zhu J. X., Pei W. B., Wang C. Y., Huang L., Yao C., Yan Q. Y., Huang W., Loo J. S. C., Zhang Q. C., Small 2014, 10, 4874. [DOI] [PubMed] [Google Scholar]
  • 126. Xu G., Yan Q. L., Lv X. G., Zhu Y., Xin K., Shi B., Wang R. C., Chen J., Gao W., Shi P., Fan C. H., Zhao C. C., Tian H., Angew. Chem., Int, Ed. 2018, 57, 3626. [DOI] [PubMed] [Google Scholar]
  • 127. Ma T., Zheng J., Zhang T., Xing D., Nanoscale 2018, 10, 13462. [DOI] [PubMed] [Google Scholar]
  • 128. Sarkar S., Ha Y. S., Soni N., An G. I., Lee W., Kim M. H., Huynh P. T., Ahn H., Bhatt N., Lee Y. J., Kim J. Y., Park K. M., Ishii I., Kang S. G., Yoo J., Angew. Chem., Int, Ed. 2016, 55, 9365. [DOI] [PubMed] [Google Scholar]
  • 129. Zhou X., Lee S., Xu Z. C., Yoon J., Chem. Rev. 2015, 115, 7944. [DOI] [PubMed] [Google Scholar]
  • 130. Jain P. K., Lee K. S., El‐Sayed I. H., El‐Sayed M. A., J. Phys. Chem. 2006, 110, 7238. [DOI] [PubMed] [Google Scholar]
  • 131. Jain P. K., Huang X. H., El‐Sayed I. H., El‐Sayed M. A., Acc. Chem. Res. 2008, 41, 1578. [DOI] [PubMed] [Google Scholar]
  • 132. Zou W. Q., Visser C., Maduro J. A., Pshenichnikov M. S., Hummelen J. C., Nat. Photonics 2012, 6, 560. [Google Scholar]
  • 133. Zhou B., Shi B., Jin D., Liu X., Nat. Nanotechnol. 2015, 10, 924. [DOI] [PubMed] [Google Scholar]
  • 134. Sun Y., Feng W., Yang P., Huang C., Li F., Chem. Soc. Rev. 2015, 44, 1509. [DOI] [PubMed] [Google Scholar]
  • 135. Zhou J., Liu Q., Feng W., Sun Y., Li F., Chem. Rev. 2015, 115, 395. [DOI] [PubMed] [Google Scholar]
  • 136. Zhou J., Liu Z., Li F. Y., Chem. Soc. Rev. 2012, 41, 1323.22008740 [Google Scholar]
  • 137. Wang F., Han Y., Lim C. S., Lu Y., Wang J., Xu J., Chen H., Zhang C., Hong M., Liu X., Nature 2010, 463, 1061. [DOI] [PubMed] [Google Scholar]
  • 138. Xiong L., Chen Z., Tian Q., Cao T., Xu C., Li F., Anal. Chem. 2009, 81, 8687. [DOI] [PubMed] [Google Scholar]
  • 139. Liu Q., Sun Y., Yang T., Feng W., Li C., Li F., J. Am. Chem. Soc. 2011, 133, 17122. [DOI] [PubMed] [Google Scholar]
  • 140. Park Y. I., Kim J. H., Lee K. T., Jeon K.‐S., Na H. B., Yu J. H., Kim H. M., Lee N., Choi S. H., Baik S.‐I., Kim H., Park S. P., Park B.‐J., Kim Y. W., Lee S. H., Yoon S.‐Y., Song I. C., Moon W. K., Suh Y. D., Hyeon T., Adv. Mater. 2009, 21, 4467. [Google Scholar]
  • 141. Wu S., Han G., Milliron D. J., Aloni S., Altoe V., Talapin D. V., Cohen B. E., Schuck P. J., Proc. Natl. Acad. Sci. USA 2009, 106, 10917. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 142. Nam S. H., Bae Y. M., Park Y. I., Kim J. H., Kim H. M., Choi J. S., Lee K. T., Hyeon T., Suh Y. D., Angew. Chem., Int. Ed. 2011, 50, 6093. [DOI] [PubMed] [Google Scholar]
  • 143. Xie X., Liu X., Nat. Mater. 2012, 11, 842. [DOI] [PubMed] [Google Scholar]
  • 144. Zhou L., Wang R., Yao C., Li X., Wang C., Zhang X., Xu C., Zeng A., Zhao D., Zhang F., Nat. Commun. 2015, 6, 6938. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 145. Barreto J. A., O'Malley W., Kubeil M., Graham B., Stephan H., Spiccia L., Adv. Mater. 2011, 23, H18. [DOI] [PubMed] [Google Scholar]
  • 146. Peng J., Xu W., Teoh C. L., Han S., Kim B., Samanta A., Er J. C., Wang L., Yuan L., Liu X., Chang Y. T., J. Am. Chem. Soc. 2015, 137, 2336. [DOI] [PubMed] [Google Scholar]
  • 147. Ding Y., Zhu H., Zhang X., Zhu J. J., Burda C., Chem. Commun. 2013, 49, 7797. [DOI] [PubMed] [Google Scholar]
  • 148. Liu Y., Chen M., Cao T., Sun Y., Li C., Liu Q., Yang T., Yao L., Feng W., Li F., J. Am. Chem. Soc. 2013, 135, 9869. [DOI] [PubMed] [Google Scholar]
  • 149. Zheng W., Zhou S., Chen Z., Hu P., Liu Y., Tu D., Zhu H., Li R., Huang M., Chen X., Angew. Chem., Int. Ed. 2013, 52, 6671. [DOI] [PubMed] [Google Scholar]
  • 150. Liu J., Liu Y., Bu W., Bu J., Sun Y., Du J., Shi J., J. Am. Chem. Soc. 2014, 136, 9701. [DOI] [PubMed] [Google Scholar]
  • 151. Liu S., Zhang L., Yang T., Yang H., Zhang K. Y., Zhao X., Lv W., Yu Q., Zhang X., Zhao Q., Liu X., Huang W., ACS Appl. Mater. Interfaces 2014, 6, 11013. [DOI] [PubMed] [Google Scholar]
  • 152. Chen Y., Zhu C., Yang Z., Chen J., He Y., Jiao Y., He W., Qiu L., Cen J., Guo Z., Angew. Chem., Int, Ed. 2013, 52, 1688. [DOI] [PubMed] [Google Scholar]
  • 153. Zhou Y., Chen W., Zhu J., Pei W., Wang C., Huang L., Yao C., Yan Q., Huang W., Loo J. S. C., Zhang Q., Small 2014, 10, 4874. [DOI] [PubMed] [Google Scholar]
  • 154. Li X., Zhao H., Ji Y., Yin C., Li J., Yang Z., Tang Y., Zhang Q., Fan Q., Huang W., ACS Appl. Mater. Interfaces 2018, 10, 39544. [DOI] [PubMed] [Google Scholar]
  • 155. Wang F., Zhang C., Qu X., Cheng S., Xian Y., Biosens. Bioelectron. 2019, 126, 96. [DOI] [PubMed] [Google Scholar]
  • 156. Yuan L., Lin W., Zheng K., He L., Huang W., Chem. Soc. Rev. 2013, 42, 622. [DOI] [PubMed] [Google Scholar]
  • 157. Xing R., Zou Q., Yuan C., Zhao L., Chang R., Yan X., Adv. Mater. 2019, 31, e1900822. [DOI] [PubMed] [Google Scholar]
  • 158. Wang W., Wu Z., Lin X., Si T., He Q., J. Am. Chem. Soc. 2019, 141, 6601. [DOI] [PubMed] [Google Scholar]
  • 159. Guo Z., Park S., Yoon J., Shin I., Chem. Soc. Rev. 2014, 43, 16. [DOI] [PubMed] [Google Scholar]
  • 160. Peng C. L., Shih Y. H., Lee P. C., Hsieh T. M., Luo T. Y., Shieh M. J., ACS Nano 2011, 5, 5594. [DOI] [PubMed] [Google Scholar]
  • 161. Wang R., Yu F., Chen L., Chen H., Wang L., Zhang W., Chem. Commun. 2012, 48, 11757. [DOI] [PubMed] [Google Scholar]
  • 162. Zhang K., Zhang J., Xi Z., Li L.‐Y., Gu X., Zhang Q.‐Z., Yi L., Chem. Sci. 2017, 8, 2776. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 163. Zhao J., Zhong D., Zhou S., J. Mater. Chem. B 2018, 6, 349. [DOI] [PubMed] [Google Scholar]
  • 164. Xu G., Yan Q., Lv X., Zhu Y., Xin K., Shi B., Wang R., Chen J., Gao W., Shi P., Fan C., Zhao C., Tian H., Angew. Chem., Int. Ed. 2018, 57, 3626. [DOI] [PubMed] [Google Scholar]
  • 165. Kim C., Favazza C., Wang L. V., Chem. Rev. 2010, 110, 2756. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 166. Wang L. V., Hu S., Science 2012, 335, 1458. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 167. Wang S., Lin J., Wang T., Chen X., Huang P., Theranostics 2016, 6, 2394. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 168. Jiang Y., Pu K., Adv. Biosyst. 2018, 2, 1700262. [DOI] [PubMed] [Google Scholar]
  • 169. Weber J., Beard P. C., Bohndiek S. E., Nat. Methods 2016, 13, 639. [DOI] [PubMed] [Google Scholar]
  • 170. Liu Y., Bhattarai P., Dai Z., Chen X., Chem. Soc. Rev. 2019, 48, 2053. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 171. Shi B., Gu X., Fei Q., Zhao C., Chem. Sci. 2017, 8, 2150. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 172. Janib S. M., Moses A. S., MacKay J. A., Adv. Drug Delivery Rev. 2010, 62, 1052. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 173. Phillips E., Penate‐Medina O., Zanzonico P. B., Carvajal R. D., Mohan P., Ye Y., Humm J., Gonen M., Kalaigian H., Schoder H., Strauss H. W., Larson S. M., Wiesner U., Bradbury M. S., Sci. Transl. Med. 2014, 6, 149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 174. Shi J., Kantoff P. W., Wooster R., Farokhzad O. C., Nat. Rev. Cancer 2017, 17, 20. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 175. Shi B., Yan Q. L., Tang J., Cin K., Zhang J. C., Zhu Y., Xu G., Wang R. C., Chen J., Gao W., Zhu T. L., Shi J. Y., Fan C. H., Zhao C. C., Tian H., Nano Lett. 2018, 18, 6411. [DOI] [PubMed] [Google Scholar]
  • 176. Sun X. T., Kong B., Wang W. S., Chandran P., Selomulya C., Zhang H. L., Zhu K., Liu Y., Yang W. L., Guo C. F., Zhao D. Y., Wang C. S., J. Mater. Chem. B 2015, 3, 4451. [DOI] [PubMed] [Google Scholar]
  • 177. Wang W. S., Sun X. T., Zhang H. L., Yang C., Liu Y., Yang W. L., Guo C. F., Wang C. S., Int. J. Nanomed. 2016, 11, 3255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 178. Zhou Z., Song J., Nie L., Chen X., Chem. Soc. Rev. 2016, 45, 6597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 179. Fan W., Huang P., Chen X., Chem. Soc. Rev. 2016, 45, 6488. [DOI] [PubMed] [Google Scholar]
  • 180. Ni D., Ferreira C. A., Barnhart T. E., Quach V., Yu B., Jiang D., Wei W., Liu H., Engle J. W., Hu P., Cai W., J. Am. Chem. Soc. 2018, 140, 14971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 181. Lucky S. S., Soo K. C., Zhang Y., Chem. Rev. 2015, 115, 1990. [DOI] [PubMed] [Google Scholar]
  • 182. Huang X., Zhang W., Guan G., Song G., Zou R., Hu J., Acc. Chem. Res. 2017, 50, 2529. [DOI] [PubMed] [Google Scholar]
  • 183. Li P., Liu L., Lu Q., Yang S., Yang L., Cheng Y., Wang Y., Wang S., Song Y., Tan F., ACS Appl. Mater. Interfaces 2019, 11, 5771. [DOI] [PubMed] [Google Scholar]
  • 184. Zhou M., Li J., Liang S., Sood A. K., Liang D., Li C., ACS Nano 2015, 9, 7085. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 185. Zhao P., Jin Z., Chen Q., Yang T., Chen D., Meng J., Lu X., Gu Z., He Q., Nat. Commun. 2018, 9, 4241. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 186. Jain P. K., Huang X., El‐Sayed I. H., El‐Sayed M. A., Acc. Chem. Res. 2008, 41, 1578. [DOI] [PubMed] [Google Scholar]
  • 187. Calvert J. W., Elston M., Nicholson C. K., Gundewar S., Jha S., Elrod J. W., Ramachandran A., Lefer D. J., Circulation 2010, 122, 11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 188. Alves M. G., Soares A. F., Carvalho R. A., Oliveira P. J., Eur. J. Pharmacol. 2011, 654, 60. [DOI] [PubMed] [Google Scholar]
  • 189. Gao Y., Yao X. Y., Zhang Y. N., Li W. M., Kang K., Sun L., Sun X. Y., Int. J. Cardiol. 2011, 152, 177. [DOI] [PubMed] [Google Scholar]
  • 190. Tang F. Q., Li L. L., Chen D., Adv. Mater. 2012, 24, 1504. [DOI] [PubMed] [Google Scholar]
  • 191. Li Z. X., Barnes J. C., Bosoy A., Stoddart J. F., Zink J. I., Chem. Soc. Rev. 2012, 41, 2590. [DOI] [PubMed] [Google Scholar]
  • 192. Jemal A., Bray F., Center M. M., Ferlay J., Ward E., Forman D., Ca‐Cancer J. Clin. 2011, 61, 69. [DOI] [PubMed] [Google Scholar]
  • 193. Kumar N., Bhalla V., Kumar M., Coord. Chem. Rev. 2013, 257, 2335. [Google Scholar]
  • 194. Mustafa A. K., Gadalla M. M., Snyder S. H., Sci. Signaling 2009, 2, 8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 195. Ni D. L., Ferreira C. A., Barnhart T. E., Quach V., Yu B., Jiang D. W., Wei W. J., Liu H. S., Engle J. W., Hu P., Cai W. B., J. Am. Chem. Soc. 2018, 140, 14971. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 196. Alexis F., Pridgen E., Molnar L. K., Farokhzad O. C., Mol. Pharmaceutics 2008, 5, 505. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 197. Huang X., Li L., Liu T., Hao N., Liu H., Chen D., Tang F., ACS Nano 2011, 5, 5390. [DOI] [PubMed] [Google Scholar]
  • 198. He C., Hu Y., Yin L., Tang C., Yin C., Biomaterials 2010, 31, 3657. [DOI] [PubMed] [Google Scholar]
  • 199. Xiao K., Li Y., Luo J., Lee J. S., Xiao W., Gonik A. M., Agarwal R. G., Lam K. S., Biomaterials 2011, 32, 3435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 200. Popovic Z., Liu W. H., Chauhan V. P., Lee J., Wong C., Greytak A. B., Insin N., Nocera D. G., Fukumura D., Jain R. K., Bawendi M. G., Angew. Chem., Int, Ed. 2010, 49, 8649. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 201. Khlebtsov N., Dykman L., Chem. Soc. Rev. 2011, 40, 1647. [DOI] [PubMed] [Google Scholar]
  • 202. Cheng Y. Y., Zhao L. B., Li Y. W., Xu T. W., Chem. Soc. Rev. 2011, 40, 2673. [DOI] [PubMed] [Google Scholar]
  • 203. Nel A. E., Madler L., Velegol D., Xia T., Hoek E. M., Somasundaran P., Klaessig F., Castranova V., Thompson M., Nat. Mater. 2009, 8, 543. [DOI] [PubMed] [Google Scholar]

Articles from Advanced Science are provided here courtesy of Wiley

RESOURCES